## INFLUENCE OF DIAZEPAM ON NEUROMUSCULAR BLOCKADE BY MUSCLE RELAXANTS

# THESIS FOR DOCTOR OF MEDICINE (ANAESTHESIOLOGY)

BUNDELKHAND UNIVERSITY, JHANSI (U.P.)

29337

#### CERTIFICATE

This is to certify that the work related to "INFLUENCE OF DIAZEPAM ON THE NEUROMUSCULAR BLOCKADE BY MUSCLE RELAXANTS", which is being submitted for the M.D. (Angesthesiology) thesis was done by Dr. Mukesh Kumar Garg under my personal supervision and guidance. The techniques and methods described were undertaken by the candidate himself and the observations recorded have been periodically checked by me.

GUIDE

(U.C. SHARMA)

M.D., D.A.,

Reeder,

Department of Anaesthesiology, M.L.B. Medical College, Jhansi.

#### CERTIFICATE

This is to certify that the work related to "INFLUENCE OF DIAZEPAM ON THE NEUROMUSCULAR BLOCKADE BY MUSCLE RELAXANTS", which is being submitted for the M.D. (Annesthesiology) thesis was done by Dr. Mukesh Kumar Garg under our personal supervision and guidance. The techniques and methods described were undertaken by the candidate himself and the observations recorded have been periodically checked by us.

CO. CITTOR

V.K.KULSHRESTIA )

M.D.

Professor

Department of Pharmacology, Department of M.L.B. Medical College, Ammenthesiology, JHANSI. M.L.B. Medical

CO-GUIDE

( CHITRA )

M.D., D.A.

Lecturer

Department of

Ammenthesiology.

M.L.B. Medical College,

JHANSI.

#### CERTIFICATE

This is to certify that the research work entitled "INFLUENCE OF DIAZEPAM ON NEUROMUSCULAR BLOCKADE BY MUSCLE RELAXANTS" which is being submitted as thesis for M.D. (Anaesthesiology) examination of Bundelkhand University, 1984 by Dr. MUKESH KUMAR GARG has been carried out in the Department of Anaesthesiology. He has put in the necessary stay in the department as per university regulations.

( B.C. JOSHI )

M.D., D.A.

Professor and Head, Department of Annesthesiology, M.L.B.Medical College, Jhansi. It is with immense pleasure that I express
my deepest sense of gratitude to my esteemed teacher
and guide Dr. U.C. Sharma, M.D., D.A., Reader in the
Department of Anaesthesiology, M.L.B. Medical College,
Jhansi, under whose able supervision and invaluable
guidance the present work has been carried out. I
find words grossly inadequate to express my
indebtness for his benevolence.

I am fortunate to have Prof.V.K.Kulshrestha, M.D., Professor in the Department of Pharmacology and Dr. Chitra, M.D., D.A. Lecturer in the Department of Amaesthesiology, M.L.B. Medical College, Jhansi as my co-guides, under whose able guidance and encouragement this work could be completed I owe a great debt of gratitude to them.

I wish to express my sincere gratefulness to my respected teachers Prof. B.C. Joshi, M.D., D.A. Professor and Head of the Department of Amaesthesiology, Dr. S.L. Srivestave, M.D., D.A. Reader in Amaesthesiology Dr. D.D. Varma, M.D., D.A. Lecturer in Anaesthesiology, Dr. P. Sahi, M.D., D.A. Lecturer in Anaesthesiology and Dr. A. Kumar, M.D., D.A. Lecturer in Anaesthesiology, M.L.B. Medical College, Jhansi.

I gratefully acknowledge the co-operation of all my friends and colleagues during conduction of my thesis work.


In the last, but not the least I am thankful to Mr. K. Lal, who has done a great job by bringing out this work in black and white, neatly and correctly.

Dated 1

( MUKESH KUMAR GARS )

### CONTENTS

1.	INTRODUCTION	1
2.	REVIEW OF LITERATURE	6
3.	MATERIAL AND METHODS	47
4.	OBSERVATIONS	55
5.	DISCUSSION	72
6.	CONCLUSION	90
7.	BIBLIOGRAPHY	
	CONTROL (Address of the	



phenomenon. Its begining can be guessed as being as old as the history of man. Man's survival on this planet has depended largely upon alleviation of his sufferings by drugs. Till today the struggle continues in laboratory and clinic for the search of better and safer drugs for the velfare of the mankind. With the introduction of a large number of drugsin last half century, a new problem of significant dimensions has cropped up in the form of interaction of various drugs with each other.

"Drug interactions form part of the normal medical practice" (Dodson).

Interactions between drugs have been observed for a better part of a century and have been described under the classical headings of antegonism, synergism and potentiation. The spectrum of drug interactions is very wide. At one end there are useful and usually undramatic drug interactions like use of atropine in organophosphorus poisoning, potentiation of action of succinylcholine by procaine and propanidid (Torda et al., 1972). At the other

hand of the spectrum are dramatic and dangerous drug interactions, such as the profound hypotension, which occurs in some patients on antihypertensive drugs if given halothane or the fatal effects of pathidine given to patients on monoamine exidese inhibitors.

Interactions between the therapeutically administered drugs can be a significant factor in determining clinical response to drug therapy.

Unlike genetic or pathological factors which may influence a patient's response to medications, drug interactions are usually the direct result of physician's therapeutic decision, and thus, the adverse clinical consequences of drug interactions are potentially preventable (Cohen and Amstrong, 1976).

administered with single anaesthetic agent like chloroform or ether. Now the encesthesiologist is exposed to a plethorn of encesthetic and non-anaesthetic drugs, increasing the frequency of patient being given many other drugs in the operative or pre/post operative period, which might not be related to encesthesis, but able to profoundly after the patient's response to drugs given during or following surgery. The encesthesiologist in particular makes use of many interactions, an

example being the use of neostigmine to reverse the action of non-depolarizing muscle relaxents.

Interactions involving commonly used drugs or potentially interacting drugs which are often likely to be given together are of more importance than those involving drugs that are infrequently used (Avery, 1976). Now a days dissepan has become one of the most commonly prescribed drug in the medical practice increasing the possibility of patient's taking it as advised by medical practioner or on his own, when he/she is proposed to undergo amount for any surgical operation. Apart from this, dissepan is usually also given on the night prior to surgery for the sound sleep and included in premedication to allay amount, apprehension and tension. It is used for the induction of amounts also.


Besides being used as a tranquilliser it has also been found to be beneficial in relieving the skeletal muscle spann in tetanus (Pemi-Pearse, 1966; Hendrickse and Sherman, 1966), stiffman syndrome (Howard, 1963) and cerebral palsied children (Marsh, 1965).

The advent of neuromuscular blocking agents has made it possible for surgeons to perform the operations that they had never dreamt they would ever be able to. The neuromuscular blocking agents have been in clinical use for over three decades. They produce muscle relaxation in relatively light but adequate planes of general anaesthesis increasing the case and efficiency with which the surgery is performed.

The key role of neuromuscular blocking agents in this field and the wide use of diesecon can prove to be a promising dry interaction. There is much controversy in the litereture recepting the effect of diagons on the neuromecular blockade produced by depolarizing and nondepolarizing skeletal muscle relaxants. Stoyner and Endresen (1965), in their first clinical study indicated that diagram did not significantly potentiate the action of d-tubocurarine of succinvictoline during abdominal operations. Later it was more emphatically suggested by Paldman and Crawley (1970 a. b) that diazenam increased the action of gallamine and decreased the deration of succinylcholine activity. It was observed by Lorenzo and Mediavilla (1973) that the commercially available solution of diazenem

enhanced the recovery from the blockade caused by detaborurarine in the cat but increased the recovery time of succinylcholine blockade.

There is still no definite opinion regarding the influence of dissepen on the neurosmecular blockede produced by muscle relevants inspiring to undertake a study to resolve these conflicts.



Muscle relexants, whether used in the jungle as poison for hunting animals or in the operation room, have always seemed highly dramatic and uniquely interesting. The pharmacologic nature of these drugs invites investigations, their sudden effectiveness commands respect, and their clinical application arouses continuing debate.

#### Neurosauscular transmission

process which begins with the synthesis and storage of acetylcholine inside motor - nerve terminals, from which the transmitter is released by nerve impulses. On arrival at the postjunctional (muscle) membrane, acetylcholine combines reversibly with receptor molecules; as a result, an increase in membrane perseebility brings about a transient depolarization at the end-plate ( the end plate potential ). The resulting ionic currents flowing across the adjacent muscle membrane are sufficiently intense to depolarize beyond the threshold and so initiate an action potential; this in term rapidly invades the whole of the muscle membrane and activates the contractile mechanism (Roberts and Gray, 1980)

The neuromuscular block may be produced at any one of the several stages in the process of transmission from nerve to muscle. In practice, however, neuromuscular block is usually achieved by modifying the activity of postjunctional (muscle) membrane in any one of the two ways.

#### Non - depolarizing block

that, while possessing sufficient affinity for
the receptors to combine reversibly with them,
does not bring about the changes in membrane
permeability which underlie the end-plate potential.
Therefore, acetylcholine competes with this drug
for occupancy of receptor sites, as only a few
are available so the end-plate potential is small.
Neuromuscular block occurs when the end-plate
potential fails to reach the threshold value and
lasts as long as the concentration of this drug
is high enough to compete effectively with
acetylcholine. Exemples are tubocurarine, gallemine
and pancuronium.

#### Decolorising block

The depolarizing dauge cause depolarization of the end-plate. Then follows a period of block due

to the reduction in membrane potential of the electrically excitable muscle membrane around the end-plate. This reduction in membrane potential is due to persistent current flow from the end-plate region and it prevents the development of further electrical activity in mucle fibres by inactivating the normal relation between membrane potential and sodium permeability, which is the basis of the all-or-none potential mechanism.

The example is suxamethonium,

#### Subocure sine

This is an alkaloid extracted from the tropical plant 'Chondrodendron tomentosum', growing near the upper reaches of Amason. It has long been used by natives of South America as poison, and they transported it in bemboo tabes, hence the name tubocurarine (Atkinson et al., 1977). In 1942, Griffith and Johnson in Montreel Introduced curare into anaesthesia.

Chemically it is a quaternary alkaloid, having an isoquinoline ring. Now a days the original formula of d-tabocurarine is thought to be incorrect and according to the new formula elucidated by Everett and coworkers (1970) this drug has only

one stable quaternary ammonium group. The structure of the other nitrogen ion will very according to the pH of the media behaving more like a tertiary ammonium compound at an alkaline pH.

The decrease in plasma d-tubocurarine
level occurs in three phases. In phase one distribution
to extracellular fluid compartment and plasma proteins
occurs. In phase two it is redistributed to nonspecific d-tubocurarine receptors throughout the
body and finally in phase three it is excreted in
urine (Walts and Dillon, 1968). Billiary system
offers an alternative pathway of metabolism.

duration of action of d-tubocurarine was 14-48 min (mean 36 min). Welts and Dillon (1968) observed that duration of action of d-tubocurarine averaged 1.5 times longer than that of gallamine. McDowell and Clarke (1968) reported that both the duration of onset of action as well as the duration of action of d-tubocurarine vere longer than pascuranium.

Kets and coworkers (1969) found different duration of action in patients of London and USAF hospital. The 90 percent recovery time at London was 27.1 ± 10.1 min and at USAF hospital 37 ± 15 min.

Benett and coworkers (1972) reported its duration of action to be 42.1 + 18.34 min. Laurence (1975) describes that its maximal action is attained in 4 min and action lasts about 30 min. Bharqava and Chatterjee (1977) concluded that its meen onset of action is 5.37 min and duration of action is 48.5 min. Atkinson and colleagues (1977) state that after the therapeutic doses of tubocurarine the muscular power returns in 15-50 min. According to Feldman (1978) recovery from complete limb musculature paralysis occurs in 30-50 min. Snow (1978) states that tabocurarine acts intravenously within 3 min and effect may last 30-40 min. Sheth and Sabnis (1982) reported that the time interval for onset of action was 252 + 48 sec while the duration of action was 31.12 ± 11.60 min.

#### Gallemine triethicdide

Pollowing the introduction of d-tubocurarine into clinical enseethesia, pharmacologists throughout the world sought for synthetic drugs with a similar action, In 1947, Bovet, Depletra and Lestrange described the muscle relaxant properties of a synthetic product gallamine triethiodide. The effects of this relaxant in man were first described by Bugusmard and Boue (1948) in France

and by Mushin and his colleagues (1949) in England.

Gallamine chemically is tri(p-diethylaminoethoxy) - benzene triethiodide.

It produces non-depolarizing neuromuscular block and is excreted by the kidneys.

Walts and Dillon (1968) observed that the duration and magnitude of the block produced by gallamine was dose dependent and its duration of action was shorter than tubocurarine.

Pionks (1972) found that its onset of action is 2-4 min and duration of action is 20-30 min. Atkinson and coworkers (1977) observed that its effect lasts about 20 min. Feldman (1978) describes that its duration of action is between 20-35 min and therefore on a comparative basis shorter than that of d-tubocurarine. Snow (1978) found its effect to last about 20-40 min. According to Calvey and Milson (1980) its speed of onset is greater than that of tubocurarine and its duration shorter.

shoth and Sabnis (1982) stated that the onset of action of gallendne was  $309.6\pm65.4$  sec and description of action was  $37.44\pm12.13$  min.

#### Pancuronium bromide

Pancuronium bromide was first synthesized in 1964 by Hewett and Savage. Buckett and coworker (1966) carried out the experimental studies with pancuronium and described its pharmacological properties. It was introduced into clinical anaesthesia by Baired and Reid in 1967.

Chemically it is 3  $\beta$ , 16 $\beta$ - dipiperidine-5 $\alpha$  -androstane-3 $\alpha$ , 17  $\beta$ -diol discrete dimethobromide.

It produces non-depolarizing type of neuromuscular block.

Penduronium is believed to be excreted mainly unchanged in the urine. It is partly metabolised by hepatic microsomal ensymes.

McDowell and Clarke (1969) found that onset as well as duration of action of pencuronism is shorter than d-tubocurazine. Dick and coworkers (1970) noted that its onset of action is 1.95 ± .07 min and duration of action 49.8 min. Kats (1971) found that it took 207 sec to abolish complete twitch response. Varma and Sharma (1971) observed that within 2 min amplitude of twitch decreased to 1-2 min and duration of parelysis was 30-65 min.

Shargava and Chatterjee (1977) observed onset of action to be 2.03 min and duration of action 51 min. Atkinson and coworkers (1977) found onset to be 2-3 min and duration 20-30 min. Vickers et al. (1978) state that duration of peripheral block varies from 30-40 min. Snow (1978) observed onset within 3 min and duration about 30-40 min.

According to Feldman (1978) the paresis produced by pancuronium lasts for about 25-40 min and "The duration of action of pancuronium could be described as lying midway between the shorter action of gallamine and longer duration of d-tubocurarine".

In 1982, Sheth and Sebnis found that the time interval for east of action was  $161.20 \pm 38.60$  sec and duration was  $50.40 \pm 15.47$  min.

#### <u>Succinvictoline</u>

In 1906 Reid Hunt and Tevenu first described the pharmacological actions of summethonium, but though they studied its effect on blood pressure they failed to observe that it causes neuromuscular block, because they were using a previously curarised animal. The drug was first used in man as a neuromuscular blocking agent by Thesleff in Stockholm (1951) and by Mayrhofer and Hassfurther (1951) in Austria. Scurr (1951) described its use in Great Britain.

Summerthonium is a synthetic bis-quaternary ammonium compound.

Summethonium is believed to act like acetycholine in man and to bring about a depolarisation type of neuromuscular block.

Pollowing en intravenous dose it rapidly undergoes ensymatic hydrolysis with plasma cholinesterase. In the absence of ensymatic process it is slowly metabolized by alkaline hydrolysis.

A very small amount is excreted unchanged in urine (Feldman .1978).

Crul and coworkers (1966) found that after intravenous injection of succinylcholine total recovery occurs in 7 min 41 sec. Kats and Ryan (1969) observed 90 percent return of twitch height in 14.6 min.

Fatz and coworkers (1969) found that
90 percent recovery time was different in London
and NewYork. In London it was 9.1 ± 2.9 min and
in NewYork 14.6 ± 3.6 min. Atkinson and coworkers
(1977) state that it causes muscular relaxation
for 3-5 min and then it rapidly disappears.
According to Snow (1978) relaxation results
within 1 min and recovery is complete within
5-15 min. Feldman (1978) states that it causes
respiratory paralysis for 2-4 min. Calvey and
Wilson (1980) state its duration of action to be
4-6 min. Blitt and coworkers (1981) concluded
that it causes disappearance of twitch within
82.3 ± 5.9 sec with a 90 percent recovery in
652 ± 63 sec.

#### DIAZERAM :

In this historical evolution, man has been able to dominate the nature by means of his technological achievements, his knowledge and his inventions, attaining an increasing control over the world and its organisation. As a result, his power over his fellow men has also increased, giving him more and more responsibility which leads, of necessity, to one existential problems is the contemporary man, with all his power and knowledge, really happy?

Several rights and desires I health, better insight into future and greater control over his destiny, but despite all this he still suffers from insecurity and from all the new problems that he has to face, which in fact account for his imperfections and limitations that inevitably generate anxiety.

Man is seeking relief from pain, suffering and naturally anxiety. Thus all possible efforts are being made to find a solution for this anxiety. The search for the substances that are able to aliminate anxiety is one of the constant concerns of modern science, and, in this context, one of the turning paints, has been the discovery of chemical agents known as bensediazepines.

In the midfifties, when a new class of therapeutic agents, the tranquillizers were shown to have considerable clinical value Roch decided to initiate a programme concerned with the search for products of this type. The initial discovery and development was the synthesis of 1, 4-bennodianepines ( Stermboch, 1980 ).

The first successful bearodiazenine. chlordiazepoxide, was developed by Strenbach's group at Roche Laboratories in the late 1950s and the tests in emissis showed interesting results (Baldesserini, 1980). This stimulated further research. Diesepen was first synthesised by Starmbach in 1961. The first pharmacological and clinical studies with dissense were reported by Randell and colleagues in the same year. In the early papers it was known as R o 5-2807 (Dundee and Wyant, 1977). Diagopan was introduced in the market near the end of 1963 under trade name of Valium (Stermbach, 1980). Much of the early work with the drug was carried out in continental Europe and was concerned with its uses in psychiatry.

Dissepon is widely used in ensesthesiology for premedication, as an induction agent and to assure a state of basel sedation allowing a series of disgnostic and therapeutic, medical and surgical procedures to be performed. Its success in the field of psychiatry, particularly in anxiety-tension states (Tender, 1962) may have been responsible for its use as preammenthatic medication, especially following a ferourable

report on the use of the related compound chlordiasepoxide by Brandt and coworkers in 1962. In 1964 Aguado - Matorras and Aquerreta of France reported their experience with a combination of diasepam and dextromoramide in neuroleptanalgesia.

Further European studies by Campan and Espagno (1964), and Blondsau (1965b) suggested its value as an induction agent. The Scandinavian workers, Stowner and Endresen (1965a, b) were first to report its use as a sole agent for this purpose. It was studied in detail by a number of groups in Britain (Cushmen, 1966; Brown & Dundee, 1969).

"Relief of the emotional factor in labour with parentrally administered diasepam" in 1965 and since them it has acquired increasing popularity in this field both as a sedative (Rouchy et al., 1966) and in the management of sclempsia (Lean et al., 1968).

Diesepem is now firmly established as a useful therapeutic agent in many fields.

Chemically diasepam is 7-chloro-1,
3-dihydro-1-methylo-5-phenyl-2H-1, 4-benzodiasepin2-one. Its structure formula is

Diszepam is administered by oral, intramuscular and intravenous routes.

intravenous comes in 2-5 min with duration of sedation 20-50 min and ammesia 3-30 min (Dundee, 1980). In a study conducted on twelve subjects Beired and Hailey (1972) reported that after 3 min a single 10 mg dose of diameter produced a plasma level of 0.8 ± 0.21 microgram per ml. The subjects were felamed, drowey and unconcerned by the venous sample being taken, but all reacted to sample taken at 50 min. The initial clinical symptoms were repeated at 6 hr and 12 hr after intravenous injection. Enterohepatic cycle was thought to be the most probable cause for this.

The findings of Gamble and coworkers (1973)
in relation to plasma levels of dissepem after
intravenous administration concide with that of
Baired and Hailey (1972).

Benzodiazepines are drugs with a dose related tranquillizing-sedative-hypnotic action and with muscle relaxant and enticonvulsant properties (Dundee, 1980).

#### MUSCLE RELAXANT PROPERTY OF DIAZEPAN

#### CLINICAL STUDIES :

in clinical anaesthesia, with dose upto 1 mg kg<sup>-1</sup> in a continuous infusion (80 mg/250 ml). Since the intensity of the hypnotic action depended largely on the rate of infusion, effective dose had to be given in 5-8 min (approximately 10 mg min<sup>-1</sup>). Annesthesia was continued with nitrous oxide and various inhalational supplements alongwith intravenous opintes. They found that abdominal relexation was adequate in about one third of their cases without curerizing agents. Recovery was not prolonged in any of their 200 patients.

In a pilot study on the muscle relaxant effect of diazepam during general anaesthesis, published in 1967, Hunter observed that out of 17 patients who received diazepam, in 4 patients 'adequate relaxation' was obtained with this drug as the only muscle relaxant and in these 4 cases no tubocurarine was required. However he stated that diasepam "produces some degree of relaxation of flat muscles of the abdominal wall, but the relaxation is insufficient for paramedian laparotomy".

Vergeno and coworkers (1970) used diazepena in doses of 0.3 to 0.4 mg/kg<sup>-1</sup> intravenously in association with berbiturete end nitrous oxide. They found that suscle relaxation produced was sufficient to perform appendicectomy or inquinal herniorrhaphy.

action of diazepem in 18 healthy subjects by studying the correlation between electromyographically recorded mean voltage and isometric tension in skeletal muscle. A significantly increased slope of voltage tension curves was found after giving diazepem, is. the mean voltage at corresponding isometric tension was about 20 percent higher. The authors therefore conclude that this finding is probably due to an action of the compound on contractile mechanisms.

Hopf and Billmann (1973) studied in volunteers the effects of dissepan on skeletal muscle. Their results show a slight effect on the contractile mechanism and/or excitability of muscle membrane.

In 1979, Bradshaw and Maddison studied the effect of dissepan at the neuromuscular junction in patients undergoing surgery under general anaesthesia. All the patients were premedicated with dissepan not more than 10 mg orally. They found that dissepan in dose of 0.16 mg/kg<sup>-1</sup> had no effect on the mechanical twitch height of the adductor pollicis muscle of the thumb when the ulner nerve was stimulated with single twitch or train of four.

#### EXPERIMENTAL STUDIES :

Dissepsm has been claimed to be about 4 to 5 times as potent as chlordissepoxide in muscle relaxant activity, as tested by the inclined-screen test and antistrychnine activity in mice, and gross muscular relaxation and spinal reflex activity in cats (Randall et al., 1961).

upon the reflex and non-reflex contractions of tibialis anterior muscle of the chloralose anaesthetised cats by Hamilton (1967). He found that it was effective in blocking the reflex contraction of this muscle under these conditions and the primary muscle relexant activity is central rather than peripheral. The same worker also conducted the experiments on the isolated rat phrenic nerve-disphragm preparation and concluded that diesepem is capable of producing a dose related inhibition of both directly and indirectly elicited contractions.

Crankshaw and Raper (1968) studied the effects of diazepem on "in vivo" and "in vitro" nerve-muscle preparations. The "in vivo" preparation was a scietic nerve-tibialis anterior muscle of chloralose-enasethetized cat. The "in vitro" preparation was an isolated rat phrenic nerve-diaphragm preparation. It was found that although diazepem could abolish polysynaptic reflex contraction, but it has no peripheral effect on the response of skeletal muscle stimulated both indirectly (through nerve) and directly.

An experimental study in isolated frog muscle on the action of dissepen was conducted by Vergano and coworkers (1969). They found that the drug has outstanding muscle relaxant properties.

Dasgupta and coworkers (1969) have also reported a neuromuscular blocking effect of diasepan at the concentration of 40 mg per ml.

They used two "in vitro" preparations (rat phrenic nerve-diaphragm and frog sciatic nerve-gastrochemius).

This effect could not be antagonised by physostigmine.

At this concentration, the authors also found a slight reduction in the response to direct muscle stimulation.

In an experiment conducted by Vergene and coworkers (1970) with isolated frog sciatic nerve-gastrocnemius preparation dissepem alone produced translant reduction in twitch height.

Prostigmine appeared to potentiate the relaxant effects of dissepem.

Experimental studies were conducted in various nerve muscle preparations by Dretchen and comprises in 1971. They observed that diszepem, when given alone, did block the contractions of the isplated chick biventer cervicis nerve-muscle

preparation and the block was dose related. The actions of emogenously applied acetylcholine and micotine were blocked by diamepam. The solvent system for the diamepam did not affect the twitch height or the emogenously applied drugs. The diamepam given intra-arterially in the dose of 5 mg also blocked contractions of dog anterior tibielis muscle and cat scietic nerve-gastrochemius muscle preparation.

Webb and Bradshew (1973) found that diazepen, in doses of 0.2-5 mg k  $\bar{g}^1$  i.v.was without any effect on the maximal twitch response of the flexor ballucis longus or soleus muscle of the cat.

Blaber (1975) using ret phremic nervedisphragm preparation, also found a neuromacular blocking effect of disappeam, when used at a concentration of 70 mg/ml. He showed that the results were influenced by the chemical composition of the solution used.

Jain, Pendey and De (1976) while conducting the experiments with tibialis anterior scietic nerve preparation of dogs concluded that discepam, in doses of 1 mg kg<sup>-1</sup>, produces no effect on the response of tibialis anterior muscle to indirect stimulation.

In 1979, Walker and coworkers observed that diamepem (valium/Roche) caused an immediate cessation of spontaneous contractions in chick embryo skeletal muscle fibres growing "in vitro". They found that between 24-48 hours later in the presence of 100 mM diamepem the relaxed muscle fibres no longer accumulate myosin synthesis.

#### SITE OF ACTION :

A number of studies have imported the knowledge of muscle relexant property of dissepen. Various probable sites of action and mechanisms of action have been suggested to explain this property of dissepen, still, no conclusion has been reached regarding this.

Randall and coworkers (1961) suggested the supraspinal structures, such as the reticular activating system and polysynaptic pathways in spinal cord, as the probable sites of action accounting for muscle relaxation produced by diasepam.

In 1966 Ngai, Tseng and Wang studied the effect of diasepam and other central nervous system depressants on spinal reflexes in cats, They found that diasepam acts upon supraspinal structures, most likely the reticular facilitatory system, in blocking the spinal polysynaptic reflexes, the spinal cord itself appeared to be relatively resistant to depression by diasepam.

Hamilton (1967) reports that diazepam more readily inhibits the contractions due to rapid (60 min<sup>-1</sup>) rather that slow rates of reflex stimulations, which is a central effect rather than a peripheral one on the myoneural junction. He further states that the experiments on the isolated rat phrenic nerve-diaphragmpreparation have shown that these compounds are capable of an action at the peripheral neuromuscular synapse, although this is not the main site of action, but with higher doses and perhaps in certain pathological conditions this should be berne in mind.

In the same year, an interference with neuronal transmission at levels above the spinal cord was suggested by Parkes (1967). Although diamepam abolishes polysynaptic reflex contraction, but it has no peripheral activity on skeletal muscle (Crankshaw and Raper, 1968).

Vergano and coworkers (1969) found that diazepam has outstanding muscle relexant property but stated "their mechanism of action is still, in some respects, obscure".

Dundee and Haslett (1970) while reviewing the actions and uses of benzodiazepines concluded that although their antienxiety effect certainly contributes to the muscle relexant action, part of it is due to a pharmacological action on polysymaptic pathway within the spinal cord or on supraspinal structures.

Feldman and Crawley (1970 a,b) concluded that dissepan acts by reducing the acetylcholine release at the presynaptic membrane.

In the same year, Hudson and Wolpert(1970)
reported that diszepsm acts primarily upon supraspinal
structures. This view was shared by Nekanishi and
Morris (1971).

Dretchen and Ghoneim (1971) although agree that central or supraspinal structures are the probable sites of action, yet they further suggest that diszepsm also has an action at the neuromuscular synapse which may involve direct muscle depression.

Another view offered the contractile mechanisms of muscles as the probable site of action (Ludin and Dubach, 1971).

The results of Hopf and Billmann (1973) showed a slight effect on the contractile mechanisms and/or excitability of muscle membrane.

Webb and Bradshew (1973) state "the unimpressive peripheral activity of diazepem on skeletal muscle under normal conditions emphasizes the importance of central sites, whether spinal or supraspinal to account for observed muscle relaxant activity in men and animals".

After reviewing the literature Martins
(1975) concluded that dissepan acts of the different
levels of the nervous system, not at the muscular
end plate. Same view was expressed by Leurence(1975).

Bradshaw and Maddison (1979) excluded the possibility of neuromuscular junction as being the main site of action of diszepam, and accepted the supraspinal structures and polysynaptic pathways in spinal cord as the probable sites of action.

Diagram has also been claimed to progressively inhibit the myosin synthesis in muscle fibres relaxed by it (Walker et.al, 1979).

Again in 1980, Dundee emphasized upon spinal cord as being the site of action of diamepem resulting in mild relaxation.

# Uses of diszepsm as muscle relexant (outside sneesthesia) :

Diamepam, a benzodiamepine derivative, is effective both as a tranquillizer and for controlling the muscle rigidity and spasm of patients with various pathological conditions.

It has been found to be useful in the treatment of tetamus (Shershin & Katz, 1964 ; Femi-Pearse, 1966 ; Hendrickse and Sherman, 1966; Dundee and Heslett, 1970), stiff men syndrome (Howard, 1963 ; Clafson et al., 1964) and other

neurological disorders resulting in muscle rigidity and spasticity (Marsh, 1965; Nathan, 1970). Diasepam has been reported to improve patient's acceptability of positive pressure ventilation (Bossa-Marrubini and Selenati, 1973).

#### DRUG INTERACTION :

The first recorded anaesthetic death could have been prevented by a knowledge of drug interactions. Morbidity and mortality still continue our understandable ignorance of the subject. On the other hand, drug interactions have helped to transform the course of anaesthetic management, which currently relies on the skilled administration of several drugs to the same patient. Certainly combination therapy and drug interactions are the basis of "balanced" anaesthesia. Hence the art lies in the avoidence of hazardous interactions and in application of useful ones (Smith, 1981).

It is abvious that most therapeutically used interactions arise as a result of pharmacological knowledge of the drugs involved. On contrast, the majority of undesirable interactions are unpredicted, and experience precedes knowledge of the machanism.

Occassionally, interactions are predicted, a good example being the prediction of the potentiation of succinylcholine by ecothiopate eye drops by McGavi in 1965, before the first case was described in 1966 (Gesztes, 1966; Pantuck, 1966).

A classification of drug interactions, on the basis of their mechanisms may aid in the prediction and thus prevention of those undesirable interactions, and suggest other therapeutically useful interactions. The drug interactions may be classified into:

#### 1. Direct Interactions :

- A. Before drug edministration: Caused by mixing of two drugs or a drug to an infusion fluid, eg. the precipitation occurs when thiopentene sodium and succinylcholine are mixed.
- B. In the body : Inectivation of haparin by protamine.

### 2. Interference with drug disposition :

### A. Absorption :

The 'second gas' effect can be considered as a drug interaction. The alveolar concentration of one gas or vapour eg. halothane, increases

due to the administration of another gas such as nitrous oxide or ether.

#### B. Protein binding :

The metabolism of pethidine is reduced in patients taking oral contraceptives as the latter prevents the pethidine gaining access to the liver cells or its microsomes.

#### C. Metabolism :

The anticholinesterase drugs reverse
the action of non-depolarizing muscle
relevants by inhibiting the metabolism of
acetylcholine.

#### D. Excretion :

Chlorpropamide and salicylates compete for the same excretion pathway in the kidney, and when administered togather, the hypoglycemic effect may be increased (Stowers et al. 1959).

# 3. Interactions at the receptor site :

These include competitive interactions as well as intereference at some part of the

pathway leading to the receptor site. Example being the potentiation of effects of neuromuscular blockers by several antibiotics like streptomycin, neomycin, kanemycin, gentamycin, polymyxin B and colistin.

# Influence of dissepen on the neuromuscular blockade by muscle relevants:

Diagram is widely used in anaesthesiology for various purposes like premedication, induction of enaesthesia and basal sedation. Because of its marked muscle relaxant property it has always been a controversial point among anaesthesiologists and pharmacologists as to whether diagram influences the effect of neuromuscular blocking agents.

In recent years, using different techniques and approaches, several workers have studied this and related questions in an attempt to clarify the problem and to elucidate the mechanisms of such an action. An amount of published material on this topic thus exists but, disappointingly enough, it sometimes shows conflicting results.

## Clinical studies

Blondeau (64, 65e, 65b) reported on his

experience with diasepam in general ancesthesis that the muscle relaxant effect remained slight but it did permit a considerable reduction in curarisation if the latter was necessary.

In 1964, Joergensen using diazepam in a double blind trial (diazepam versus placebo) as premedication in a series of cholecystectomies, found a 10 percent reduction in the dosage of succinylcholine when 20 mg of diazepam had been given intramascularly before the operation.

stowner and Endresen, in 1965e, stated in a preliminary report on their experience with Valium as an induction agent in ensesthesis that this preparation "did not significantly potentiate curarising agents like tubocurarine, diallyl-nortoxiferine (Alloferin (R)) or succinylcholine".

In the same year, Stovner and Endresen (1965b) stated in a paper read at Second European Congress of Anaesthesiology, in contrast to their previous article, that "the mean requirement of both dialityl-mor-textiferine (Alleferin ®) and tubocurarine during first hour of anaesthesia are about 8-10 percent lower when diszepem is used for induction compared to thiopentone".

Campan and Espagno (1966) found that when the diazepam was used the curarizing agents could not always be dispensed with in abdominal surgery, but their dose on the whole was diminished.

A sparing effect of dissepam on the needs of peripheral muscle relexant is mentioned without further details by Richter (1966) in relation to alcuronium.

Tonsa (1966) was unable to prove a succinylcholine - sparing effect of dissepan in comperison with thicpentone, despite the fact that dissepan considerably reduced the incidence of postoperative muscular pain caused by succinylcholine.

Commier and coworkers (1966) found no difference in the requirements of tubocurarine between two groups of patients undergoing abdominal and gynescological surgery and having received, as intromuscular premedication, dissepan (10 mg) or pathidine (100 mg).

Stowner and Endresen considered their previous findings hardly statistically significant because the number of patients were very few.

They made further studies in this field and published another article in 1969 and a paper togather with Lund (1967), in which they observed that the mean requirement of muscle relaxants were about 10 percent lower when diazepem was used for induction compared to thiopentone. This finding proved to be statistically significant. The doses of diazepem used were between 15 to 25 mg.

A muscle relexant sparing effect of diemepem on the needs of tubocurarine has been reported without further details by Toscani and Pasquali (1967).

on the muscle relexant effect of dissepam during general anaesthesis that the dose of tubocurarine needed to produce full muscular relaxation was substantially the same in a group of 9 patients who had received the dissepam and the another 13 who had during the same period been enaesthetized in exactly the same way but without this drug. However careful reading of this paper shows that in all dissepam was given to 17 patients and the above mentioned conclusion was based on data of nine patients only. In fact, in four other patients

as the only muscle relaxant and in these four cases tubocurarine was not required. Data from the remaining four patients concerning this specific point are not supplied. Diazepam was used in desage of 2.5 to 10 mg in patients with an average weight of 71 kg.

of patients and using three different anaesthetic procedures Vendramin and Luzzatto (1968) reported that there was an effective sparing of muscle relaxant when dissepen was used, both in respect of the classic barbiturate-succinylcholine anaesthesia and of neuroleptanalgesia combined with small doses of barbiturate.

Paldman and Crawley (1970a), while studying dissepan and muscle relexants, observed that although dissepan had no effect on the twitch response to a supremeximal stimulus, it did however profoundly affect the action of muscle relexants. After intravenous injection of 10 mg dissepan the neuromuscular block produced by the gallamine was increased about three folds both in degree and duration. The neuromuscular block produced by

dose of diasepem. In the same year (1970b), they published another paper, in which they confirmed their previous conclusion. In this study they used diasepem in the doses of 0.15 to 0.20 mg kg<sup>-1</sup>. The anaesthesis was maintained with nitrous oxide, oxygen and 0.5 to 1 percent halothane. They also reported that it was not possible to demonstrate a cumulative effect with diasepem if more than 15 min were allowed to elapse between the recovery from one dose of the drug and administration of the next.

More recently, Stovner and colleagues (1971) studied the influence of the induction agent (dissepan and thiopentone) on the requirements of gallamine and pancuronium in females undergoing lower abdominal surgery. They stated, "The doses (in mg sq m<sup>-1</sup> of body surface) of these relaxants were 7-8 percent lower and displayed a lower inter-individual variation with dissepan compared with thiopentone".

Dretchen and coworkers (1971) did not find any alteration in recovery rate of any of the three neuromecular blocking agents (d-tubocurarine, gallamine and decemethonium) by the use of diametem (in doses of 0.3 to 0.6 mg kg<sup>-1</sup> intravenously) in human subjects.

After a comprehensive review of the literature on this subject, Martins (1975) concluded that dissepan slightly reduces the doses of neuromuscular blocking agents required during anaesthesis.

In their study of interaction of dissepen with non-depolarizing muscle relevants Jain and coworkers (1976) found no significant changes in the mean time of easet of action, the mean intensity of action and mean 75 percent recovery time of d-tubocurarine (0.3 mg kg<sup>-1</sup>) produced by dissepen 10 mg in human subjects.

In a clinical study conducted by Bradshaw and Maddison (1979), it was observed that dissepte 0.16 mg kg<sup>-1</sup> had no effect on mechanical twitch height of adductor pollicis muscle of the thumb when the ulnar nerve was stimulated at the wrist. Further they concluded that dissepte in the same dose had no effect on the depth or recovery of neuromuscular blockade produced by summethonium, tubocurarine, pancuronium, fazadinium or alcuronium.

Dundee (1980) used disrepem extensively in ensesthesia. He commented that while the bensodiasepines have a mild muscle relaxant effect, their use during operation did not affect the requirement of myoneural blocking drugs.

Asbury and coworkers (1981) investigated the possibility of an interaction between diazepam and pancuronium in six patients undergoing general anaesthesis maintained with fantanyl, droperidol and nitrous oxide. Neuromuscular blockade was controlled using a feedback mechanism which automatically adjusted the rate of injection of pancuronium to maintain between 71.4 and 72.9 percent blockade. Diazepam 0.14 mg kg lintravenously produced blood concentrations within the therapeutic range, but did not produce consistant changes in the level of blockade, pancuronium concentration in the blood or pancuronium consumption measured over 20 min.

## Experimental studies :

The effect of dissepen on neuromiscular blockade produced by muscle relaxants has also been studied on various animals.

Cheymol and coworkers (1967) observed, in rabbits, that diasepam potentiated the effects of tubocurarine and gallamine, but does not interfere with the effects of succinylcholine. In their studies these authors used the head drop method as well as an "in vitro" neuromuscular preparation (sciatic nerve-tibialis anterior muscle). The doses of diazepam that showed interaction with tubocurarine were twice as great as those showing interaction with gallamine. These authors also reported that diazepam, in high doses (10 mg kg<sup>-1</sup>), increases the amplitude of the muscular contraction slicited by direct muscular stimulation.

Sensone and colleagues (1967) using the head drop method in the rabbit to study the interaction between tubocurarine and dissepen, arrived at results very similar to those of Cheymol and coverdors (1967) but with lower doses (0.166 mg kg<sup>-1</sup>).

Mougdil and Pleuvry (1970) using "in vitro" neuromuscular preparation (rat phrenic nerve-disphregm) did not observe any potentiation of the effects of either tubocurarine or gallemine but reported an increase in the amplitude of contractions elicited by direct muscular stimulation.

It was reported by Vergano and coworkers (1970) that in isolated frog sciatic nerve - gastrochemius preparation diazepam alone produced transient reduction in twitch height and in association with tubocurarine and gallamine muscle twitch was more markedly reduced than that produced by the drug along and for longer duration.

Southgate and Wilson (1971), using an "in vivo" preparation ( cat sciatic nerve - gastrochemius muscle), failed to demonstrate any interaction between therapeutic doses of diazepem (intravenous) and either summethonium or gallamine.

In the same year Webb and Bradshaw (1971) while conducting experiments with cets failed to find any elteration in depth or time course of block produced by either gallamine or tubocurarine which could be contributed to dissepon (0.2 -0.4 mg kg<sup>-1</sup>). In addition they found that dissepon in higher doses (1 mg kg<sup>-1</sup>) enhanced the rate of

recovery from block without affecting the depth of block of either drug, but this weak affect was attributed to the solvent system of dissepem.

Dretchen and colleagues (1971) in addition to their studies in humans, also investigated the interaction of dissepem with neuromuscular blocking drugs in several animal nerve-muscle preparations. They concluded that the drug "did not alter the recovery slope of blockade produced by tubocurarine, decemethonium or gallamine. In low doses the commercially available drug given intra-arterially reversed the myomeural blockade produced by both depolarizing and non-depolarizing blockers. However, this property was due to the solvent system of the drug".

Lorenzo and Mediavilla (1973) reported
that commercially available solution of diazepem
enhanced the recovery from the blockade caused
by d-tubocurarine in cat but increased the recovery
time of the succinylcholine blockade.

In 1973, Webb and Bradshaw confirmed their previous findings and concluded that dissepsm does not possess any prejunctional blocking activity.

Jain and coworkers (1976) found that diezepem in a bolus dose of 5 mg did not influence a pre-existing partial block by d-tubocurarine, gallamine or pancuronium. But a significant increase in both the degree and duration of block was observed when diazepem and d-tubocurarine were given simultaneously, suggesting an agonist action in diazepem. On the contrary simultaneous use of diazepem and gallamine caused a significantly less intense block of tibialis muscle twitch tensions as compared to gallamine alone, suggesting an antagonistic action.

gastrocnemium muscle preparation of dogs, Sharma and Sharma (1978) found that commercially available solution of dissepam (Calmpose) significantly reversed the neuromuscular blockade produced by a non-depolarizing agent like gallamine but augmented the blockade produced by a depolarizing agent like succinylcholine.

MATERIAL & METHOD

## MATERIAL AND METHODS

This study was conducted on the patients presenting themselves for surgical operations at M.L.B. Medical College Hospital, Jhansi. The aims and objects of the study are :-

- 1- To essess the effect of dissepsm on the neuromuscular blockade produced by depolarizing and non-depolarizing muscle relements viz succinylcholine, gallamine, pancuronium and tubocurarine respectively.
- 2- To assess the duration of action of blockade produced by succingleholine, gallamine, paneuronium and tubocurarine.
- 3- To essess the neuromecular blockede activity of diesepen, if any.

# SELECTION OF CASES

Adult patients of both the sexes, scheduled for routine surgical operations, were included in the study. Preference was given to the cases undergoing surgical operations which

did not necessitate profound muscular relaxation.

Each patient was subjected to a detailed history and clinical examination.

The following routine investigations were conducted :-

- 1- Hasmoglobin estimation.
- 2- Total and differential leukocyte count.
- 3- Erythrocyte sedimentation rate.
- 4- Complete chemical and microscopic urine examination.

All the patients were in good physical state, without any neuromuscular disease and were not receiving any drug known to influence the action of neuromascular blocking drugs. All the cases selected for the study belonged to ASA Grade I and II.

#### GROUPING OF THE PARTEURS

Pathents were divided into two main groups, according to the time when the dissepant was administered. The proprietery preparation of dissepant used was 'Calmpose', which has a composition as follows:

# Each two ml of calmpose contains :-

Diesepem U.S.P. - 10 mg

Bensoic scid I.P. - 6 mg

Benzyl Alcohol I.P. - 0.03 ml

Sodium benzoate I.P. - 94 mg

Ethyl Alcohol I.P. - 0.2 ml

Propyleme Glycol U.S.P.-0.8 ml

Water for injection q.s. 2 ml

It was administered in doses of 0.13 to 0.17 mg kg<sup>-1</sup> body weight.

# GROUP A :

Patients of this group received the dissepan intravenously 3-5 min before the dose of muscle relaxant which was to be studied in those particular patients.

#### GROUP B :

the patients of this group received the disnepon intrevenously at the start of recovery from the muscle relevant drug.

The patients of both the groups were surther subdivided into four subgroups each

according to which one of the four muscle relevants was given to them.

Subgroups A1 and B1 - Received succinylcholine.

Subgroups A2 and B2 - Received gallamine.

Subgroups A3 and B3 - Received pencuronium.

Subgroups A4 and B4 - Received tubocurarine.

All the patients served as control for themselves. This helped in minimizing the error arising due to the individual variation in response to muscle releasent drugs.

The petients were prepared for general anaesthesis for routine surgery. Vitals were recorded before the administration of premedicalit drugs.

#### TECHNIQUE OF ANAESTHESIA

### I - PREMEDICATION .

The presence thetic medication consisted of etropine 0.65 mg and pathidine 1 mg kg<sup>-1</sup>. Both the drugs were administered intremscularly one hour before surgery.

### II- INDUCTION +

An introvenous line was set up in a big wein and infusion of 5% Descrose  $^{\rm D/}{\rm W}$  was started.

All the subsequent drugs were given through this line.

After pre-coygenation for five minutes induction was carried out by intravenous thispentone sodium (Intraval® sodium) 2.5% in a dose sufficient to abolish the eyelash reflex (approximately 4-5 mg  $\log^{-1}$ ).

## III- INTUENTION :

Succinylcholine chloride (Scoline<sup>®</sup>)

1-1.5 mg kg<sup>-1</sup> was administered introvenously to
produce muscular relaxation for endotracheal
intubation. After annesthetising the laryne with
4% sylocaine, a cuffed endotracheal tube of appropriate
size was passed into the trachea and connected to a
non-rebreathing circuit and intermittent positive
pressure ventilation instituted.

## IV- MALIFIENANCE OF ANALISTIESIA :

A non-rebreathing technique incorporating the Ruben non-rebreathing valve with high gas flow was used. The gas mixture consisted of nitrous calde and oxygen in ratio of 614. Helothene was edded to this mixture as and when needed.

As the twitch height in response to peripheral nerve stimulation attained the maximum magnitude the muscle relevant (under study) was given intravenously in the following doses:


1.	Succinylcholine	0.94	to	1.11	mg	149-1
2.	Gallenine	1	to	1.78	mg	kg <sup>-1</sup>
3.	Pencuronium	0.04	to	0.05	mg	kg-1
4.	Tubocurarine	0.13	to	0.25	mg	200-1

After the return of twitch height to the basal level fifteen minutes were allowed to elapse before the same second intravenous dose of the same muscle relexant to the same patient was given.

The first dose of muscle relexant drug served as control for that particular patient while the effect of dissepsm was observed on the second dose of that muscle relexant.

## MONITORING OF MEUROMUSCULAR SLOCKAUE :

In the present study the recording technique used to monitor the neuromascular blockade was a modification of the method described by Danaka (1964). Same technique was used by Yazma and Shanna (1971) while studying paneuronium bromide.



When the patient was placed on the operation table, the arm was extended laterally on an arm board and fixed to it by adhesive strappings. The hand was fixed in midprone position, immobilizing all the fingers except thumb to eliminate the error produced by movement of fingers other than the thumb.

The thumb was attached to an isometric writing lever by the help of a non-stretchable silk thread. No pulley or any other device was used in between the thumb and writing lever to aliminate any undue resistence affecting the recording of twitch height( Fig 1).

The writing lever recorded the twitch height in response to ulner nerve stimulation on smoked paper mounted on hymograph.

the skin over wrist of immebilized ann was cleaned with spirit. Two sterile 24 gauge steel hypodemic needles were placed subcutaneously 1-2 cm apart close to the lateral side of pisiform bone as the ulner nerve passed along this course (Romanes, 1973). These hypodemic needles served well as subcutaneous electrodes.

The ulner nerve was stimulated using a Cinex nerve stimulater NS-2 with frequency of 0.1 Hz. The duration of each stimulus was 300 us and the intensity was adjusted in each case to get sufficient height of curve.

The maximum twitch height obtained prior to the injection of muscle relaxant under study served as basal recording. After the injection of muscle relaxant the maximum twitch suppression was considered as peak of action. The return of twitch height to the basal level was considered as the recovery from muscle relaxant drug.

With the help of above criteria the following parameters were measured using a stop watch.

- I- Onset of action : It was measured from the last drops of injection of muscle relexant to the attainment of peak of ection.
- II- Duration of action : It was measured from peak of action to the recovery from the given dose of muscle relaxant.


The recordings on the smoked paper were fixed by dipping it into 5% solution of sheller in methylated spirit.

#### REVERSAL :

At the end of surgical operation nitrous caide was turned off and full exygenation started. If a non-depolarizing muscle relaxant was used for study then it was followed by inj neostigmine 2.5 mg and inj atropine 1.2 mg. Both the drugs were given intravenously and very slowly. Then as the reflexes returned extubation was done. Patients were shifted out of operation theatre in full conscious state.

#### POST OPERATIVE .

The patients were watched for respiratory sufficiency and muscle strength.



## OBSERVATIONS

In the present work the influence of diazepes on the neurosuscular blockade by suscle relaxants was studied. To fulfill the purpose of the study it was approached in the following way:-

(A) Firstly the normal onset and duration of action of muscle relaxants along with twitch suppression produced by them were assessed. Total 62 cases were studied out of which 20 received succinylcholine (32.25%), 16 gallamine (25.81%), 16 pancuronium (25.81%) and 10 tubocurarine (16.13%) as shown in table 1.

TABLE NO. 1
Showing distribution of cases into different droups

S.No.	Muscle relevent	No.	of cases	(M)
1.	Succinylcholine	20	(32.25%)	
2.	Gallemine	16	(25.81%)	
3.	Panctronium	16	(25.81%)	
4.	Tubocurarine	10	(16,13%)	

0.1

(B) Secondly the onset and duration of action along with the twitch suppression produced by above mentioned muscle relaxants were assessed when these were used with dissepen. These values were compared with the normal values assessed in the same patients to see any influence of dissepen on them. For this purpose the cases were divided into various groups as shown in table 2.

Showing distribution of cases into various groups

s.No.	Muscle relexant	Dissepen given before musele relexant No.	Dissepen gives the start recovery No.	of No.
1. Succ	inylcholine	10	10	20(32,25%)
2. Onll	smine	8	8	16(25,81%)
. Panci	ugonium	8	8	16(25,81%)
. Tubo	ruxurine			10(16,13%)
	real	34		62

(c) Thirdly it was assessed whether dissepam itself has some muscle relaxant property or not. It was done by observing its effect on twitch height in response to electrical stimulation (n = 31).

TABLE NO. 3
Showing type of surgery done

No.	Type of surgery	No. (%)
1.	General surgery	29 (46,77%)
2.	Orthopsedic surgery	20 (32.26%)
3.	Oynaecological and Obstetrical surgery	12 (19.36%)
4.	Ophthalmic surgery	1 ( 1.61%)
	20tal	62

In the present study out of 62 cases,

29 cases underwent general surgery, 20 cases

Orthopsedic surgery, 12 cases gynecological and

obstetrical surgery and 1 case ophthalmic surgery

(Fig 2).

Fig 2. PIE DIAGRAM SHOWING DISTRIBUTION
OF VARIOUS TYPES OF SURGERY.




TABLE NO. 4

Showing age - distribution in patients

Age group (Tears)	Sactinglaholine No.	Gallanine No.	Pancuronium No.	Aubocurarine No.	E. a.	Total No. (%)
16 - 20		n	-	*	2	13 (20.97%)
2 . 1		•	•	n	40	(12.90%)
26 - 30	-	*1	m	***	10	6 (9.68%)
31 - 35	~	un.	-	N	10	10 (16.13%)
36 - 40	•	N	*	wi	**	11 (17,74%)
57 - 73	N	•	•	•	*	4 ( 6.45%)
\$6 - 50	M	H	'n	•	00	(12.90%)
55 - 55	N	•	•	•	M	(3.23%)
fotel	20	97	16	94	3	

Mean age (± SEM) in 62 patients is 33.18 ± 1.40 years, in succinylcholine group 34.40 ± 2.72 years, in gallemine group 31.06 ± 2.38 years, in pencuronium group 38.38 ± 2.55 years and in tubocurarine group 25.80 ± 2.55 years.

TABLE NO. 5

Mowing weight distribution in the patients

Meight of the petients (Kg)	Succinyleholine No.	Gallamine No.	Pancuronium No.	Pancuronium Tubocurarina No. No.	4 3	Total No. (%)
26 - 30		a	•	-	~	2 (3.23%)
31 - 35	•	•	N	eri.	*	4 ( 6.45%)
36 - 40		•	**	n	S	(27.42%)
59 - 19	n	N	*	-	0	9 (14.51%)
05 -99	•	~	•	m	70	20 (32,26%)
51 - 55	N	•	m	ri	-	7 (11.29%)
26 - 60	•	m	1	*	(r)	3 (4.84%)

Mean weight (+ SZM) in 62 patients is 45.48 ± 0.89Kgin succinylcholine group 45.80 ± 1.23 Kg, in gallemine group 45.38 ± 2.26 Kg, in pancuronium group 46.81 ± 1.55 Kg and in tubocurarine group 42.90 ± 2.40 Kg.

Sex of the patient	Succiny	Succinyl choline No. (%)	Gellamine No. (%)	Pencuronium No. (X)	Nubocurarine No. (%)	70tal No. (%)
i	10	10 (50%)	7 (43.75%)	8 (50%)	(80%)	29 (46.77%)
į	2	10 (30%)	9 (56.25%)	(%) 8	(%09) 9	33 (53.23%)
Perel	8		16	16	10	62

TABLE BO. 7

Showing distribution of AGA grading in patients

13 (65%)		No. (%) No. (%)	No. (%)
	(43.75%) 4 (25%)	(%09) 9	30 (48.39%)
ASA grade II 7 (35%) 9 (56.25%	9 (56.25%) 12 (75%)	* 60%	32 (S1.61%)


showing comparison of enset of action of muscle relaxants


TABLE NO. 8

hast of Letion (sec)	Succinyl choline No.	Callenine	Pancuronium No.	Tubocurarina No.
0 - 30	•	•		
8 . 7	*		1	1
8 . 3		•	-	•
91 - 120	•	m	•	
121 - 150		-	•	
151 - 180		•	•	N
181 - 220		~	•	N
211 - 240			•	*
241 - 270		0.	1	64
Total	30	16	16	10

med) and tubocurarine longest (218 ± 9.17 sec) onset of action with gallamine in In non-depolarizing muscle relexants pancuronium has the shortest (128.75 + 6.89 between tubocurarine and gallamine (P & 0.01) and tubocurarine and pancuronium between (152.5 ± 6.42 sec). The difference between onset of action of gallamine The mean onset of action (+ SEM) of succinylcholine is 54 ± 3.51 sec. and pancuronium is significant (P / 0.05) while it is highly significant (b C 0.01) (Fig 3).

Fig 3. COMPARISON OF ONSET OF ACTION OF MUSCLE RELAXANTS






PABLE NO. 9

Showing comparison of duration of action of muscle relaxants

Duration of action (min)	Succinyl choline No.	Gallamine No.	Pancurontum No.	Tubocurarine No.
9.1- 10	18			
10.1 - 15				
15.1 - 20				•
20.1 - 25		•	l +-	
25.1 - 30	•	ı ın	•	•
30.1 - 35		· cu	4 4	
35.1 - 40		100		4
40.1 - 45		. •	. 1	•
45.1 - 50			1 1	1 1
50.1 - 55	į	1		n un
Total	56		1	
	*	16	97	C

and tubocurarine the longest (46.87 ± 2.52 min) duration of action with paneuronium In non-depolarizing muscle relaxents gallamine has the shortest (31.43 ± 1.55 min) The mean duration of action (+ SEM) of succinylcholine is 7.61 ± 0.45 min. significant between tubocurarine and gallamine (P / 0.01) and tubocurarine in between (34.46 & 1.13 min). The difference between duration of action of gellaming and pancuronium is statistically insignificant while it is highly pencuronium (P & 0.01) (rig 4).

Fig 4. COMPARISON OF DURATION OF ACTION OF MUSCLE RELAXANTS







TABLE NO. 10

Showing the comparison of twitch suppression produced by muscle relaxants

itch experession	Succinylcholine	Gellanine	Pancuronium	Pancuronium Tubocurarine
			•	MO.
3 2		N	•	•
05 - 19	•	m	m	•
21 - 60		m	*	**
64 - 70		1	**	•
71 - 80	*	**	**	et
06 - 10	* * * * * * * * * * * * * * * * * * *	•	•	~
91 -100	20	•	<b>s</b> n	m
Total	20	16	16	3

(75.63 ± 5.02%) - tubocurarine (76 ± 9.97%) are not statistically significant (Pig 5). by non - depolarizing muscle relaxants i.e. gallamine (73.13 ± 6.17%) - pancuronium The difference between the mean (+ SEN) twitch suppression produced

Fig 5. COMPARISON OF TWITCH SUPPRESSION PRODUCED
BY MUSCLE RELAXANTS






TABLE NO. 11

Showing comparison of various perameters of muscle relaxant groups

S.Mo.	Parameter	Succinylcholine	Gallamine	Pancuronium	Tubocurarine
i	No.of cases (x)	20 (32.25%)	16 (25.61%)	16 (25,61%)	10 (16.13%)
i	Age in years Hean t skin	34.40 ± 2.72	31.06 ± 2.38	38.38 ± 2.55	23
ė	Sex distribution - Male No. (%)	10 (50%) 10 (50%)	7 (43.75%) 9 (56.25%)	(50%)	
	Weight in by Mean + 984	65.80 ± 1.23	45.38 ± 2.26	46.81 ± 1.55	2
oi .	ASA Grade - ASA I No. (%) - ASA II No. (%)	13 (65%) 7 (35%)	7 (43.75%) 9 (56.25%)	4 (25%)	
3	Chast of action in sec Nean 4 SEM	56 ± 3.51	152.5 ± 6.42	128.75 ± 6.89 218 ± 9.17	218 ± 9.17
	Duration of action in min. Nean ± SEM	7.61 ± 0.65	31.43 ± 1.55	34.46 + 1.13	46.87 4 2.43
ó	Nitch suppression in X. Mean ± SEM	100 ± 0	73.13 ± 6.7	75.63 ± 5.09 76.00 ± 9.97	76.00 ± 9.97

TABLE NO. 12

Showing comparison of onset of action of muscle relaxants with and without dissepon (Dissepon given 3-5 min before muscle relaxant).

Sl. Mo.	Muscle relement	Onset of ection without dissepen Hean ± SEM sec	Onset of action with dissepen Mean ± SEM sec	Algolficance
1.	Succinylcholine	57 ± 5.98	50 ± 4.72	Not algalficant
2.	Callenine	151,85 ± 12,01	177.5 ± 10.97	Not significant
3.	Peneuronium	126.25 £ 5.95	129.75 ± 5.49	Not significant
4.	Twocoextoo	208 ± 14,94	230 ± 14.81	Not significant

The difference between the onset of action, with and without dissepon, is statistically not significant in any of the four muscle relevants.

TABLE NO. 13

Showing comparison of easet of action of muscle relaxants with and without diamepem (Diamepem given at the start of recovery).

al.	Auscle relement	Onset of action without dissepan Mean ± SEM pec	Onset of action with dissepon Mean ± SEM sec	Significance
1.	Succinyleholine	51,00 ± 3,79	49.00 ± 2.34	Not significant
2.	Callenine	153.75 ± 5.65	160.00 ± 7.07	Not significant
3.	Personal	131,25 ± 12,87	132,50 ± 12,20	Not significant
4.	?wocuserine	228,00 ± 10,18	242.00 ± 7.53	Not significant

These is no statistically significant difference between the onset of action, with and without dissepen, in any of the four mascle relevants.

TABLE NO. 14

Showing comparison of duration of action of muscle relexants with and without dissepan (Dissepan given 3-5 min before muscle relexant).

51. Bo.	Muscle relevant	Duration of action without diesepen Mean ± SEM min	Duration of action with diesepen Mean ± SSM min	849	nificance
1.	Succinyloholine	7.70 ± 0.44	7.01 ± 0.41	Not alg	nificant
2.	Gallamine	30.66 ± 2.43	45.06 ± 4.68	P	0.05
3.	Panettenius	34,29 ± 1.46	56.60 ± 2.97	P	0,01
4.	Tubocurazina	46.54 ± 3.56	65.17 ± 3.99	P	0.01

There is no statistically significant difference in mean curation of action of succinylcholine with and without dissepen. With dissepen there is a significant increase in the mean duration of action of gallemine by 46.9% (2 0.05). Pencuronium by 65.06% (2 0.01) and tobocurazine by 40.03% (2 0.01).

TABLE NO. 15

Showing comparison of duration of action of muscle relements with and without diezepem (Diezepem given at the start of recovery).

Mo.		Duration of action without dissepon Mean ± SRM min	Duration of action with dissepon Mean ± SEM min	Significance
1,	Succinylcholine	7.51 ± 0.80	6.68 ± 0.50	Not significant
2.	Gallenine	32.19 ± 2.04	49.08 ± 2.07	P 0.01
3.	Pancusynium	34,62 ± 1,79	49,66 ± 3,83	P 0.01
4.	Tubocurarine	47.20 ± 3.96	63.73 ± 2.72	P 0.01

The difference in mean director efection of succinglichatine with and without dissequents etatistically imaignificant. But with dissequent there is a significant increase in the mean direction of setion of sellemine by \$2.4%

(9 0.01), Pensusonium by 43.44% (P 0.01)

and telepomeratine by 35.02% (P 0.01).

#### TABLE NO. 16

Showing comparison of twitch suppression produced by muscle relements with and without dissepen (Dissepen given 3-5 min before muscle relement).

Si.	Auscle relevent	Switch suppression without discepan Mean ± SEM %	Twitch suppression with dissepen Mann ± SEM %	Significance
1.	Succinylcholine	100.00 ± 0.00	100.00 ± 0.00	**
2.	Gallenine	71.88 2 9.25	94.37 ± 4.37	P 0.05
3.	Paneatronium	76.87 ± 8.39	98,12 ± 1,31	P 0.01
4.	Tubocuterine	77.00 ±12.18	99.00 ± 1.00	P 0,01

In non-depolarising muscle relatents there was a significant increase in the mean twitch suppression after administration of dissepse. It was 31,20% in gallamine group (P 0.05).

27,66% in passessession group (P 0.01) and 20,57% in tubocusarine group (P 0.01).




Fig 6a Showing the influence of dissepam on the neuronmiscular blockade activity of succinylcholine (dissepam given 3-5 min before succinylcholine).




Fig 6b Showing the influence of discopen on the meuromuscular blockeds activity of succinylcholine (discopen given at the start of recovery).




Fig 8a Showing the influence of diszepam on the neuromuscular blockade activity of pancuronium (diszepam given 3-5 min before pancuronium).





Fig 8b Showing the influence of dissepan on the neuromuscular blockeds activity of pancuromium (dissepan given at the start of recovery).



Pig 9a Showing the influence of diazepam on the neuromuscular blockede activity of tubocurarine (diazepam given 3-5 min before tubocurarine).





Fig 9b Showing the influence of diazepam on the neuromuscular blockade activity of tubocurarine (diazepam given at the start of recovery).

property of dissepan, its effect was observed on twitch height in response to electrical stimulation in the 31 patients who received dissepan before muscle relaxant. It was observed that dissepan, when given alone, did not produce any alteration in the twitch height.

No difficulty was faced during the reversel from non-depolarizing muscular blockade and none of the patient included in the study experienced any respiratory insufficiency post-operatively.





#### DISCUSSION

When one considers the many types of chemical compounds used in modern therapeutics, it is not surprising that some of these modify the action of muscle relaxants. In general such substances may interfere with neuromuscular transmission or may influence relaxants by actions at other sites. Some such side effects are well known. Others based on animal experiments on many different species and under varying conditions, are more difficult to assess precisely. Nevertheless, it would be unwise for anaesthetist to ignore the possible risk they suggest.

Dissepsm is one of the most commonly used drugs in ansesthesis. It is used for a number of purposes like premedication and induction.

Dissepsm undoubtedly possesses a muscle relaxant property. Doughty (1970) reported a patient who received 10 mg of dissepsm intravenously and developed apnose with muscular relaxation for two hours! For this muscle relaxant activity

both central (Egai et al., 1966) and peripheral (Ludin and Dubach, 1971) sites of action have been suggested. Hence there is a probability that if diasepam is given along with muscle relaxants, it might influence their neuromuscular blocking action. There seems to be a considerable difference of opinions concerning the influence of diasapam on the action of muscle relaxants as is evident from the foregoing. A number of workers who conducted the investigations in this field arrived at different conclusions and still controversies surround this problem.

The present study was conducted on the patients presenting themselves at M.L.B. Medical College Hospital, Thansi for various ailments requiring surgical intervention. Patients of ASA grade I and II only were included. Patients of ASA grade III, IV and V were spared as the severe systemic diseases are known to alter the patient's response to muscle relexants.

The solution of dissepsm is irritant, therefore, it was given only in large vein to prevent the occurence of thrombosis.

Halothane was used as and when needed in low concentrations. Kats and Gissen (1967) have reported that inhalation of 1-2% halothane does not cause any decrease in the twitch height response to ulnar nerve stimulation.

In the earliest studies the methods to observe the effects of muscle relexant drugs were based on the clinical observations, grip strength measurements in conscious volunteers and tidal volume studies in ancesthetized patients. None of these methods proved entirely satisfactory.

of determining the degree of neuromuscular block is to stimulate a motor nerve with an electric current and observe or record the contraction of muscle innervated by that nerve. The respiratory muscles themselves are difficult to test, but the hand muscles are readily accessible in most patients. Such muscles are particularly valuable because they are more 'semsitive' to the relaxants than the respiratory muscles, becoming paralysed earlier and staying paralysed longer (Churchill Davison, 1965). The mechanical twitch height of adductor politicis muscle provides an excellent quide to the

degree of relaxation produced by muscle relaxant drug (Kats, 1965). Therefore, in this study, the degree and duration of neuromuscular block produced by muscle relaxants were measured by recording the adduction movement of thumb (produced by contraction of adductor pollicis muscles) on a smoked paper in response to stimulation of ulner nerve at wrist by a nerve stimulator. Sterile 24 gauge steel hypodermic needles were used as subcutaneous electrodes. The subcutaneous electrodes were preferred over surface electrodes as it is difficult to maintain a constant position with latter and skin necrosis may occur due to pressure of surface electrodes if used for prolonged periods (Kats, 1965; de Jong, 1966). The intensity of stimulus was adjusted in each case to get sufficient height of curve. The height of twitch response obtained is the function of muscle tension developed. Although this method provides rather a crude record, but once the twitch response of constant amplitude is obtained, it provides an accurate and reliable record of responses to neuromiscular blocking drugs (Baraka, 1964) .

## Muscle relexants

## Tubocurarine :

Its onset of action (218  $\pm$  9.17 sec) and duration of action (46.87  $\pm$  2.52 min) both were found to be longest as compared to other muscle relaxants studied. The onset of action of tubocurarine is significantly longer than gallamine ( P<0.01 ) and pancuronium ( P<0.01 ) (Table 8). Its duration of action also is significantly longer than gallamine ( P<0.01 ) and pancuronium ( P<0.01 ) (Table 9). Tubocurarine produced a mean twitch suppression of 76  $\pm$  9.97% in doses of 0.21  $\pm$  0.04 mg/kg and it is not significantly different from the degree of neuromuscular blockade produced by gallamine and tubocurarine (Table 10).

Different workers have observed different onset and duration of action of tubocurarine. Kats and coworkers (1969) found significantly different duration of action at London and New York. The enset of action of tubocurarine observed in the present study is comparable to those reported by Laurence (1975) and Sheth and Sabnis (1962). Various workers have reported its duration of action in a range of

30-50 min (Kats and Gissen, 1967; Bhargava and Chatterjee, 1977; Atkinsen et al., 1977; Feldman, 1978). The duration of action observed in the present study is within this range. A shorter duration of action (31.12 ± 11.60 min) was reported by Sheth and Sabnis (1982). Its onset as well as duration of action are significantly longer than pancuronium as reported by McDowall and Clarke (1969). The duration of action of tubocurarine was found to be 1.5 times longer than gallamine. Walts and Dillon (1968) also obtained similar results.

# Gallamine triethiodide :

The onset of action of gallamine (152.5  $\pm$  6.42 sec) was found to be in between those of tubocurarine and pancuronium. Its differences from pancuronium (P < 0.05) and tubocurarine (P < 0.01) were statistically significant (Table 8). The duration of action of gallamine was shortest (31.43  $\pm$  1.55 min) of all the non-depolarizing muscle relaxants. Although the difference between duration of action of gallamine and pancuronium was statistically not significant, it was significant between gallamine and tubocurarine

(P<0.01) (Table 9). Gallamine produced a mean twitch suppression of  $73.13 \pm 6.17\%$  with doses used in the study (Table 10).

The onset of action observed in the present study is in accordance with Monks (1972) who found it to be 2-4 min. Its duration of action is reported to be in a range of 20-40 min (Feldman, 1978; Snow, 1978; Sheth and Sabnis, 1982) and our observations comapre favourably with them.

Welts and Dillon (1968) and Calvey and Wilson (1980) concluded that its speed of onset is greater than that of tubocurarine and its duration of action shorter. We also reached the same conclusion.

## Pancuronium bromide :

The onset of action of pancuronium was found to be shortest (128.75  $\pm$  6.89 sec). It is significantly shorter than gallemine (P < 0.05) and tubocurarine (P < 0.01) (Table 8). The duration of action of pancuronium came to be 34.46  $\pm$  1.13 min which is significantly shorter than tubocurarine (P < 0.01) but the difference between pancuronium and gallemine was not significant (Table 9). In the doses

used in study it produced a mean twitch suppression of  $75.63 \pm 5.02\%$  (Table 10).

The onset of action observed in the present work compares favourably with the workers who reported it in a range of 2-3 min (Bhargava and Chatterjee, 1977; Atkinson et al., 1977; Snow, 1978). The duration of action of pancuronium is reported to be in a range of 25-45 min (Varma and Sharma, 1971; Vickers et al., 1978; Atkinson et al., 1977; Snow, 1978; Feldman, 1978) and our results are within this range. The omset and duration of action of pancuronium were found to be shorter than tubocurarine which is in accordance with the observations of McDewall and Clarke (1969) and Feldman (1978). Contrary to this Sheth and Sabnis (1962) reported that the duration of action of pancuronium is longer than tubocurarine.

#### Secringicholine :

The mean onset of action of succinylcheline was found to be  $54 \pm 3.51$  sec (Table 8) and mean duration of action  $7.61 \pm 0.45$  min (Table 9). It produced 100% twitch suppression with the doses used in the study (Table 10).

The onset of action observed in the present study is in accordance with Snew (1978) who stated that relaxation results within one min. The duration of action of succinylcholine was found to be within 5-15 min by various other workers (Crul et al., 1966; Snow, 1978; Calvey and Wilson, 1980; Blitt and coworkers, 1981) and our observations are within this range.

In the present study the effect of diameter on neuromuscular blockade produced by muscle relaxants was observed in the same patient in whom the normal duration of action of that muscle relaxant was assessed. This method reduced error that would have been caused by individual variation. Feldman and Crawley (1970 b) using the same technique reported that it was not possible to demonstrate a cumulative effect with gallamine in doses used 1% more than 15 min were allowed to elapse between recovery from one dose of the drug and administration of the next.

The patients were divided into two groups.

One group received diameter (0.15 mg/kg ix) 3-5 min

before giving muscle relaxant (Group A) and the other

group received the same dose of diameter at the start

of recovery from neuromuscular blockede (Group B).

onset of action of the muscle relaxants namely succinvicholine, galiamine, pancuronium and tubocurarine, when diazepam was not used, was 57 ± 5.98 sec, 151.25 ± 12.01 sec, 126.25 ± 5.95 sec and 200.0 ± 14.94 sec respectively, whereas when the diasepam was used the mean onset of actioncame to be 50 ± 4.72 sec, 127.5 ± 10.97 sec, 128.75 ± 5.49 sec and 230 ± 14.81 sec respectively. Although there appears to be difference in our observations after diasepam protreatment but it is not statistically significant (Table 12).

Our results are in comformity with Jain and coworkers (1976) who also failed to observe any effect of dissepsm on the onset of action of tubocurarine in humans and of tubocurarine and gallamine in dogs.

It was observed that in group B (Table 13) the mean easet of action of succinvicholine, gallamine, panearonium and tubocurarine came to be 51 ± 3.79, 153.75 ± 5.65, 131.25 ± 12.87 and 228 ± 10.18 sec respectively when dissepan was not used. On using dissepan at the start of recovery from smacle

relaxant activity the mean onset of action came to be  $49.0 \pm 2.34$ ,  $160.0 \pm 7.07$ ,  $132.5 \pm 12.20$  and  $242.0 \pm 7.33$  sec respectively. The difference observed in this group was also statistically not significant.

In this group discepem was used when recovery from suscle relaxant activity started, as such it can not have any effect on the onset of action. As similar results were seen in group A also it can be logically inferred that dissepam does not influence the onset of action of these muscle relaxants.

In our series while observing the influence of dissepsm on the duration of action of muscle relexants in group A (Table 14), it was observed that after dissepsm pretreatment although duration of action of succinylcholime was reduced from 7.70 ± 0.44 to 7.01 ± 0.41 min, but this was not statistically significant. In case of non—depolarising muscle relexants, namely gallamine, pameuronium and tubocurarine, when dissepsm was used their duration of action increased by 46.97%, 65.06% and 40.00% respectively which was significant

i.e. to say that there occurred a significant one and a half times increase in the direction of action of non-depolarizing muscle relaxants.

Our results are in conformity with Cheymol and coworkers (1967) who observed that the diamenam potentiated the effects of tubocurarine and callamine, but did not interfere with the effects of succinylcholine. Same conclusion was also drawn by Sansone and coworkers (1967) using tubocurarine and Vergano and coworkers (1970) using tubocurarine and gallamine. Our results compare favourably with the workers who in their studies concluded that diamenam permits a considerable reduction in curarisation during general ansesthesia. (Blondeau, 1964, 1965 a. b # Stowner and Endresen, 1965 b # Campan and Espaceso, 1966). Feldman and Crawley (1979 a.b) observed that dissecon increased the duration of block produced by callamine by three folds. Stover and colleagues (1971) found that after using dissepan the doses of pencuronium and gallamine were reduced by 7-8%.

In the present study we failed to observe any significant alteration in the duration

of action of succinylcholine by diazepam and it compares favourably with the earlier reports (Stovner and Endresen, 1965a , Tonsa, 1966 ; Bradshaw and Maddison, 1979 ; Southgate and Wilson, 1971).

In group B (Table 15) there was also decrease in duration of action of succinylcholine from 7.51 ± 0.80 to 6.68 ± 0.50 min, when diameters was given at the start of recovery, but it was not statistically significant. In case of non-depolarizing muscle relevant namely gallamine, pancuronium and tubocurarime the duration of action increased by 52.47%, 43.46% and 35.02% respectively and this increase was statistically significant.

In the present series, the degree of muscular blockade was assessed by measuring the twitch suppression produced by muscle relexants.

In group A (Table 16) it was observed that, suscingleholize (given in doors of 1 mg kg<sup>-1</sup>)

caused 160% twitch suppression when either dissepsm
was given before the muscle relaxant or it was not given at all. While with the non-depolarizing muscle relaxants namely gallamine, parauronium and tubocurarine these was increase of twitch suppression by 31.29%,

27.64% and 28.57% respectively when the dissepan was used. This increase in case of non-depolarizing muscle relevants is significant.

Our results compare favourably with those of Peldman and Crawley (1970a, b) who observed a three fold increase in the degree of blockade produced by gallamine with diasepam, Vergano and coworkers (1970) using tubocurarine and gallamine and Jain and coworkers (1976) who used gallamine.

In group B (Table 17) also the twitch suppression produced by succinylcholine was 100% irrespective of fact whether diasepan was given at the time of start of recovery or not. While when diasepan was given at the time of starting of recovery from muscle relaxant activity of gallamine, pancurenium and tubocurarine there was slight increase in the twitch suppression as compared with that when diasepan was not used (from 74.38 ± 8.73 to 81.25 ± 7.24 %, 74.38 ± 6.08 to 81.25 ± 6.66 % and 75.0 ± 8.64 to 79.0 ± 9.52 % respectively). This increase is statistically not significant, and can be explained due to the cumulative effect of the first dose of the muscle relaxants.

In the present study it was observed that dissepam alone produced no effect on the twitch height of adductor pollicis muscle in response to electrical stimulation of ulnar nerve. It was also observed in the various clinical (Feldman and Crawley, 1970 a, b; Bradshaw and Maddison:, 1979) and experimental studies (Webb and Bradshaw, 1973; Jain and coworkers, 1976).

Therefore in the present study we observed that after giving dissepan there occurred a significant increase in the duration of action as well as the degree of blockade produced by nondepolarizing muscle relevants namely callamine, pancurenium and tubocurarine while the duration of action of succinylcholine remained unaffected. This increase could have been caused by discopen, which possesses an undisputable muscle relexant property. Feldman and Crawley (1970 a. b) concluded that dissepen influenced the action of muscle relexants by inhibiting presynaptic release of acetylcholine. For other workers also suggested a peripheral site of action (Mamilton, 1967; Drotchen et al., 1971; Endin and Dubech, 1971; Hopf and Billman, 1973). But in the present study

we observed that dissepan alone did not affect the twitch height, therefore, it can be concluded fairly that dissepan does not possess any peripheral action. Most of the workers, who investigated the site of action of dissepan are also of the opinion, that diametem exerts muscle relaxant activity by acting at a site other than peripheral. Supraspinal structures, such as reticular activating system and polysynaptic pathways in the spinal cord have been considered as the probable sites of action accounting for muscle relexation produced by diasepam (Randall and coworkers, 1961; Ngai et al., 1966; Webb and Bradshaw, 1973; Bradshaw and Maddison, 1979). Zbinden and Randall (1967) who studied its muscle relaxant property in dystonic - athetoid children with cerebral palsy, contributed it to its anti-enviety effect. However, the clinical experience of Marsh (1965) and Howard (1963) indicates that at least part of its beneficial effect is due to a pharmacological action on polysymaptic pathways within spinal cord or on suprespinal structures.

We, like Peldman and Crawley (1970 b), observed that there command potentiation of the effect of non-departming muscle relexants after giving dissepan when the muscle relexants were

administered 15 min after recovery from the effect of first dose. This could have been due to cumulative effect of the first dose of non-depolarizing muscle relaxant (tubocurarine, paneuronium and gallamine) as the workers like Webb and Bradshaw (1973) have observed marked cumulative effect persists even if the dose interval is 30 min to 1 hour apart.


Contrary to this Peldman and Crowley (1970 b) had reported that there is no cumulation of effect when the dose is repeated 15 min after recovery from first dose.

observed in the present study is not alone due to effect of dissepan but also due to cumulative effect as one can not deny the fact that there is cumulative effect of second dose of drug even if it is administered at the interval of 30 min to 1 hour (Webb and Bradshaw, 1973).

there is controversy regarding the site of action of dissepan and we have found that it does not have any paripheral action. The potentiation of effect of non-depolarizing muscle

relexants indicates that dissepan should have site of action other than peripheral. Martins (1975) also arrived at a similar conclusion. If this be the case then there should also be potentiation of the effect of depolarising muscle relexant like succinylcholine, which was not observed by us. This can be explained by the fact that there had been masking of the effect of diageness due to tachyphylaxis with subsequent doses of succinylcholine (It was the third dose of succinvicheline in the same patient on which the influence of diagonam was studied as the first dose was administered to facilitate the endotrachesl intubation and second dose served as control). Tachyphylaxis has also been reported by Crui and coworkers (1966).

In view of the Soregoing, it is evident that the dissepan potentiates the action of non-depolarizing muscle relexants but it is not very marked. Therefore, dissepan can be used safely with the muscle relexants. However, it should be kept in mind that this potentiation may be dangerously aggrevated in certain pathological conditions or if the dissepan is used in very high doses.





## CONCLUSION

After carefully analysing the observations, obtained in the series of 62 patients studied in the present work, we concluded that

- The enset and duration of action of tubocurarine were 218 ± 9.17 sec and 46.87 ± 2.52 min respectively.
- 2. The onset and duration of action of gallamine were 152.5  $\pm$  6.42 sec and 31.43  $\pm$  1.55 min respectively.
- 3. The easet and duration of action of pancuronium were 128.75 ± 6.89 sec and 34.46 ± 1.13 min respectively.
- 4. The enset and duration of action of succinylcholine were 54  $\pm$  3.51 sec and 7.61  $\pm$  0.45 min respectively.
- 5. Among non-depolarising muscle relaxents studied in the present work pancuronium acted most repidly and the tubocurarine was slowest with callegine in between.
- 6. The duration of action of tubocurarine was significantly longer than that of gallamine

- and pancuronium while difference between the latter two was not significant.
- 7. Diesepem did not affect the conset of action of any of the muscle relaxant studied in the present work.
- 8. The observed potentiation of duration of action and degree of blockade produced by non-depolarizing muscle relaxants after giving dissepen might be partly due to dissepen, by virtue of its muscle relaxant property, and partly due to cumulative effect of first dose of muscle relaxant.
- 9. The duration of action of succinylcholine was not altered, whether the dissepen was given before it or at the start of recovery from its action. This might have been due to masking of potentiating effect of dissepen by techyphylaxis.
- 10. The site of action of dissepom is not peripheral accounting for its muscle relaxant property.

## 



- Aguado Matorras, A., and Aquerreta, M L.E.
   (1964). Neurolepatanalgesic avec Valium Palfium
   (Neuroleptanalgesia with Valium plus destromoreside).
   Ann. Anesth. Franc., 5, 722.
- 2. Asbury, A.J., Henderson, P.D., Brown, B.H., Turner, D.J., and Linkens, D.A. (1981). Effect of diagepea on pancuronium induced neuromuscular blockade maintained by a feed back system. Brit. J. Ameesth., 53, 959.
- 3. Atkinson, R.S., Rushman, G.B., and Lee, J.A. (1977).

  A Synopsis of Ampesthesia. Sth edn, P. 301, Bristols

  John Wright and Sons Ltd.
- 4. Avery. G.S. (1976). Drug Treatment, 2nd edn, P. 1252. Edinburgh : Churchill Livingstone.
- 5. Deired, E.S., and Halley, D.M. (1972). Delayed recovery from a sedetive : Correlation of plasma Levels of discopen with clinical effects after eval and introvenous edministration. Brit. J. Amaesth., 44, 803.

- 5. Baired, W.L.M., and Reid, A.M. (1967). The neurosuscular blocking properties of a new steroid compound, Pancuronium bromide. Brit. J. Annesth., 39, 775.
- 7. Beldessarini, R.J. (1980). Drugs and the treatment of psychiatric disorders; in The Pharmacological Basis of Therapeutics (eds A.G. Gilmen, L.S.Goodman and A. Gilman), 6th edn, P. 437. New York:

  Macmillan.
- 8. Baraka, A. (1964). The influence of carbon dioxide on the neuromecular block caused by tabonserine chloride in human subjects. Brit. J. Anaesth., 36, 272.
- 9. Benett, E.J., Dalal, F.Y., and Fischer, M. (1972).

  Pavulon in open heart procedures, M.E.J. Anses.,

  3. 413.
- 10. Bepke, F., Lowe, 2., and Wasmen, B. (1965).

  Relief of emotional factor in labour with
  parentrally administered dissepan. Obstekrics
  and Gynaecology, 26, 852.
- 11. Shargeva, 8., and Chatterjee, 8. (1977). A comparative clinical study of pencuronium bromide with 4-tubecurarine chloride. Ind. J. Annesth., 25. 295.

- 12. Blaber, L.C. (Unpublished report) : quoted by Martins, H.F. (1975).
- 13. Blitt, C.D., Carlson, G.L., Rolling, G.D.,
  Nemeroff, S.R., and Otto, C.W. (1981). A comparative
  evaluation of pretreatment with non-depolarizing
  neumonuscular blockers prior to the administration
  of succinylcholine. Amesthesiology, 55, 687.
- 14. Blondeau, P. (1964) : quoted by Martins, N.F. (1975).
- 15a. Blondeau, P. (1965) : quoted by Martins, H.P. (1975).
- 15b. Blondom, P. (1965) : Diamopem et anesthesic generale. Cah. Anesth., 13, 207.
- Bovet, D., Deplerze, F., and de Lestrange, Y. (1947):
   quoted by Feldman, S. (1978).
- 17. Bosse Marrubini, M., and Selenati, A. (1973).

  Clinical use of diasepem in intensive therapy:
  indications and results: in The Benzodiasepines
  (eds S. Gerattini, B. Mussini and L.O. Randall).
  p. 565. New York: Rawen Press.
- 18. Bradehay, E.G., and Maddison, S. (1979). Effect
  of dissepan at the neurosmuscular junction; A
  clinical study. Brit. J. Amaesth., 51, 955.
- 19. Brandt, A.L., Lai, S.C.Y., and Briggs, B.D.(1962). Trial of chlordisseposide as a presspecthetic

- 20. Brown, S.S., and Dundee, J.W. (1968). Clinical studies of induction agents. XXV: Diesepem. Brit. J. Aneesth., 40, 108.
- 21. Buckett, W.R., and Bonta, I.L. (1966). Pharmacological studies with NA 97 ( 2  $\beta$ , 16  $\beta$  Dipiperidine  $5\alpha$ -androstane  $3\alpha$ , 17  $\beta$  diel discetate dimethobromide). Fed. Proc., 25, 718.
- 22. Calvey, T.N., and Wilson, H. (1980). Muscle relaxant drugs and their antagonists; in General Anaesthesia, Vol. 1 (eds T.C. Gray, J.F. Numn and J.B. Utting), 4th edn, P. 319, London: Butterworths.
- Campan, L., and Espagno, M.T. (1964). Note sur le diasapam en enesthesiologic. Ann. Anasth. Franc.,
   711.
- 24. Campan, L., and Bapagno, M.T. (1966). Bilan actual du diamapan en enesthesiologic. Ann. Amesth. Franc., 7. 193.
- 25. Chegeol, J., Van den Driessche, J., Allain, P., Eben - Monsei, E. (1967). Diezepem et cureriention. Annesth. Apalg. Resnium., 24, 329.
- 26. Churchill Davidson, H.C. (1965). The 6-tobecurarine Gilcome. Ansethesiology, 26, 132.

- 27. Cohen, S.N., and Armstrong, M.F. (1974). Drug
  Interactions, A handbook for clinical use, 1st
  edn. P. vi. Baltimore : Williams & Wilkins Company.
- 28. Cormier, A., Goyette, M., Keen Szanto, M., and Rheault, J. (1966). A comparison of the action of maperidine and diazepem in anesthetic premedication. Canad. Anaesth. Soc. J., 13, 368.
- 29. Crankshaw, D.P., and Raper, C. (1968). Some studies on peripheral actions of mephenesin, methocarbemol and diasepen. Brit. J. Pharmacol., 34, 579.
- 30. Crul. J.F., Long, G.J., Brunner, E.A., and Coolen, J.M.W. (1966). The changing pattern of neuromuscular blockade caused by succinylcholine in man.

  Amesthesiology, 27, 729.
- 31. Cushman, R.P.A. (1966). Discepem in intrevenous encerthesis. Lencet, 1, 1042.
- 12. Desgupta, S.R., Rey, N.M., and Mulderjee, B.P.

  (1969). Studies on the effect of dissepen (Valium)

  on neuromiscular transmission in sketelel muscles.

  Ind. J. Physiol. Pharmecol., 13, 79.

- 33. de Jong, R.H. (1966). Controlled relexation;
  II. Clinical management of muscle relexant
  administration. J.A.M.A., 198, 1163.
- 34. Dick, W., and Droh, R. (1970). Originalien Experience with Pavulon. Der Angesthesist, 5. 173.
- 35. Dodson, M.E. Mechanisms of drug interactions.
  Anaesthesia rounds, 8, 2.
- 36. Doughty, A. (1970). Unexpected danger of diagepem. Brit. Med. J., 2, 239.
- 37. Dretchen, K., Ghoneim, M.H., and Long, J.P.

  (1971). The interaction of dissepen with myoneural
  blocking agents. Anesthesiology, 34, 463.
- 38. Dundee, J.W. (1980). Sedatives, tranquillisers and hypnotics; in General Anaesthesia, Vol. 1 (eds T.C. Gray, J.F. Nunn and J.E. Utting), 4th edn, P. 273. London; Dutterworths.
- 39. Dundee, J.W., and Heslett, W.H.K. (1970). The Benzodiezepines, A review of their actions and uses relative to enseethetic practice. Drit. J. Amaesth., 42, 217.

- 40. Dundee, J.W., and Wyant, G.M. (1977).

  Tranquillizers ; in Intravenous Anaesthesia,
  1st edn, P. 275, Edinburgh : Churchill
  Livingstone.
- 41. Everett, A.J., Lowe, L.A., and Wilkinson, S. (1970). Revision of structure of (+) tubocurarine and (+) chondrocurarine, Chem. Communications, 16, 1020.
- 42. Feldmen, S. (1978), Heuromusculer blocking drugs; in A Practice of Ancesthedia (ed H.C. Churchill-Davidson), 4th edn, P. 865, London; bloyd Luke Ltd.
- 43s. Peldman, S.A., and Crawley, B.E. (1970). Diesepem and muscle relevants. Drit. Med. J., 1, 691.
  - 43b. Feldman, S.A., and Crawley, B.E. (1970).

    Interaction of diesepem with muscle relement
    drugs. Brit. Ned. J., 2, 336.
  - 44. Femi-Pearse, D. (1966). Experience with dissepon in teterns. Brit. Med. J., 2, 862.
  - 45. Gamble, J.A.S., Medkay, J.S., and Dundee, J.W.

    (1973). Plasma levels of dissepsm (correspondence).

    Brit. J. Ancesth., 45, 1085.

- 46. Gesstes, T. (1966). Prolonged apnoes after Summethonium injection associated with eye drops containing an anticholinesterase agent. Brit. J. Ansesth., 38, 408.
- 47. Griffith, H.R., and Johnson, G.E. (1942). The use of curare in general anaesthesia.

  Anasthesiology, 3, 418.
- 48. Hemilton, J.T. (1967). Muscle relexant activity of chlordiazepoxide and diazepam. Canad. Thysiol. Pharmacol. 45, 191.
- 49. Hendrickse, R.G., and Sherman, P.M. (1966).

  Tetapus in childhood : Report of a therapeutic

  trial of disrepsm. Brit. Med. J., 2, 860.
- 50. Hemett, C.L., Savage, D.S., Lewis, J.J., and
  Sugme, M.F. (1964). Anticonvulsant and
  intermenronal blocking activity in some synthetic
  amino-steroids. J. Pharm. Pharmacol., 16, 765.
- 51. Hopf, H.C., and Billmann, P. (1973). The effect of dissepon on motor nerves and skeletal muscle. Z. Newrol., 204, 255.

- 52. Howard, F.M. jr. (1963). A new and effective drug in the treatment of the stiff men syndrome : Preliminary report. Pro. Mayo Clin., 38, 203.
- 53. Madson, R.S., and Holpert, M.K. (1970).

  Central muscle relexant effect of dissepan.

  Neurophermacology, 9, 481.
- 54. Huguenerd, P., and Boue, A. (1948) : quoted by Feldman, S. (1978).
- 55. Runt, R., and Taveau, R. (1906). On physiological action of certain choline derivatives and new methods for detecting choline. Brit. Med. J., 2, 1788.
- 56. Funter, A.R. (1967). Diesepem as a muscle relement during general ancesthesia. Brit. J. Angesth., 39, 633.
- 57. Jain, P.D., Pandey, K., and De, M. (1976).

  Effect of diesepen on neuromuscular transmission and its interaction with non depolarizing muscle relevants. Appeath. Intensive care, 4122.

- 58. Joergensen, H. (1964). Premedicinering med diasepem. Valium. Jaemfoerelse med placebo i en dubbel blind undersoekning. Nord. Med., 72, 1395.
- 59. Katz, R.L. (1965). A nerve stimulator for the continuous monitoring of muscle relexant action. Amesthesiology, 26, 832.
- 60. Katz, R.L. (1971). Modification of action of pancuronium bromide by succinylcholine and halothane. Anasthasiology, 35, 602.
- 61. Ketz, R.L., and Gissen, A.J. (1967). Memoranscular and electromyographic effects of halothene and its interaction with d-tubocurarine in man. Amesthesiology, 28, 564.
- 62. Ketz, R.L., Hormen, J., Seed, R.F., and Conard, L. (1969). A comparison of the effects of summethonium and tubocurarine in patients in London and New York. Brit. J. Ameesth., 41, 1041.
- 63. Katz, R.L., and Ryan, J.F. (1969). The neuromecular effects of summethonium in men. Brit. J. Ameesth., 41, 381.
- 64. Leurance, D.R. (1975). Clinical Pharmacklogy, 4th
  eth. P. 14.11. Edinburgh & ELSS and Churchil
  Livingstone.

- 65. Lean, T.H., Retnom, S.S., and Sivesemboo, R. (1968). Use of benzodiasepines in the management of eclampsia. Journal of Obstetrics and Gymeecology of British Commonwealth, 75, 856.
- 66. Lorenzo Fernandez, P., and Medievilla Martinege,
  A. (1973): quoted by Sharma, K.K., and Sharma,
  U.C. (1978).
- 67. Ladin, N.P., and Dubach, K. (1971). Action of dissepen on muscular contraction in man. 2. Neurol., 199. 30.
- 68. Mersh, H.O. (1965). Diasepsm in incapacitated cerebral palsied children. JAMA, 191, 797.
- 69. Mertins, H.P. (1975). The influence of dissepan on the dosage of muscle relexants during Amgesthesia. Amgesthesist, 24, 1.
- 70. Maythoder, G., and Massfurther, M. (1951) : quoted by Peldman, S. (1978).
- 71. Mc Dowall, S.A., and Clarke, R.S.J. (1969).

  A clinical comparison of pancuronium with

  d-tubocumarine, Ameesthesia, 24, 581.
- 72. Mc Gevi, D.D.M. (1965). Depressed levels of serum pseudocholinesterase with ecothicpete fedide eye drops. Lancet, II, 272.

- 73. Monks, P.S. (1972). The reversal of nondepolarizing relaxants. A comparison of tubocurarine, gallamine and pancuronium. Anaesthesia, 27, 313.
- 74. Mougdil, G., and Pleuvry, B.J. (1970). Disseptem and neuromuscular transmission. Brit. Med. J., 2. 734.
- 75. Mishin, W.W., Wien, R., Mason, D.F.J., and Langston, G.T. (1949). Curare-like actions of tri-(diethylaminoethoxy)-benzine triethyliodide.

  Lancet, 1, 726.
- 76. Nekemishi, P., and Morris, F.H. (1971). Effect of discepts on rat spinel reflexes. J. Neurol. Sci., 13, 189.
- 77. Nethan, P.W. (1970). The ection of dissepon in neurological disorders with excessive motor activity. J. Neurol. Sci., 10, 33.
- 78. Ngei, S.H., Tseng, D.T.C., and Weng, S.C. (1966).
  Effect of diameter and other central nervous
  system depressents on spinal reflexes in cats:
  A study of site of action. J. Pharmecol. Exp.
  Ther., 153, 344.

- 79. Olafson, R.A., Mulder, D.W., and Howard, F.M.
  (1964). Stiff men syndrome: A review of
  literature, report of three additional cases
  and discussion of pathophysiology and therapy.
  Mayo Clin. Proc., 39, 131.
- 80. Pantuck, E.J. (1966). Ecothiopate eye drops and prolonged response to summethonium. Brit. J. Amaesth., 38, 406.
- 81. Parkes, M.W. (1967). The pharmacology of diazepom; in Diazepom in Anaesthesia (eds F.P. Knight and C.G. Burgess), P. 1. Bristol : Wright.
- 82. Randall, L.O., Heise, G.A., Schallek, W., Bagdon, R.E., Bansiger, R., Boris, A., Moe, R.A., and Abrems, W.B. (1961). Pharmacology and clinical studies on dissepan. Current Therapeutic Research, 3, 405.
- 83. Richter, R. (1966). L'emploi combine en neuroleptanalgesie du diazepem et de la diallyl-nor-toxiserine. Accesth. Analg. Resnim., 23, 371.
- 84. Roberts, D.V., and Gray, T.C. (1980).

  Neuromascular transmission and neuromascular

  block; in General Anaesthesia, Vol. 1 (eds T.C.

  Gray, J.P. Num and J.E. Utting), 4th edn, P. 301,

  Landon : Butterworths.

- 85. Romanes, G.J. (1973). Cumminghem's Manual of Practical Anatomy, Vol. 1, 1st ELBS edn, P. 96. Edinburgh : ELBS and Oxford University Press.
- Of. Rouchy, R., Blondeau, P., LeCennelier, R., Crese, J., and Grosleux, P. (1966). Diesepon by the intravenous route in Obstetrics. Press Medicale, 74, 312.
- 87. Sensone, M., Aulisie, G.A., and Marino, A. (1967) : quoted by Martins, H.F. (1975).
- 88. Sourr, C.F. (1951). A relaxent of very brief action. Brit. Med. J., 2, 831.
- 69. Sharme, K.K., and Sharme, U.C. (1978). Influence of diageom of the effect of neuromuscular blocking accents. J. Pharm. Pharmec., 30, 64.
- 90. Shershin, P.H., and Katz, S.S. (1964). Diazepem in the treatment of tetamus. Report of a case following teeth extraction. Clin. Med., 71, 362.
- 91. Sheth, V., and Sebmis, S.S. (1982). Qualitative comparison of parauronium bromide with gallemine and d-tubocurarine, Ind. J. Ansesth., 30, 69.

- 92. Smith, N. Ty. (1981). Dangers and opportunities; in Drug Interactions In Anaesthesia (eds M. Ty. Smith, R.D. Miller and A.M. Corbascio), P. 1, Philadelphia : Lea & Pebiger.
- 93. Snow, J.C. (1978). Mermal of Annesthesia, 1st Asian edn, P. 113, Tokyo : Igaku Shoin Ltd.
- 94. Southgate, P.J., and Wilson, A.B. (1971).

  Pharmacological interaction of lorezepam with
  thicpentone sodium and skeletal neuromuscular
  blocking drugs. Brit. J. Pharmacol., 43, 434 P.
- 95. Stermbach, L.H. (1980). The benzodiazepine story; in Dempodiazepines Today and Tomorrow (eds R.G. Priest, U.V. Filho, R. Anrein and M. Skrete), P. S.: MTP Press 1-td.
- 96. Starmbach, L.H., and Reeder, E. (1961)

  Ominasolines and 1. 4-bensodiamepines. II.

  The rearrangement of 6-chloro-2 chloromethyl-4phasylquinespline 3-omide into 2-eminoderivatives
  of 7-chloro-5-phasyl-3H-1, 4-bensodiamepine
  4-omide, J. Org. Chem., 26, 1111.
- 97a. Showner, J., and Endresen, R. (1965). Disrepan
  in intravenous asserthesis (correspondence).
  Lamout, 2, 1998.

- 97b. Stovner, J., and Endreson, R. (1965). Intravenous anaesthesia with diamepem. Acta Anaesth. Scand. Suppl., 24, 223.
- 98. Stovmer, J., and Endresen, R.(1969). Diasepsm es an induction agent. Amesthesist, 18, 242.
- 99. Stovner, J., Endresen, R., and Lund, I. (1967).

  Comparison of diallyl-nor-toxiferine and
  d-tubocurarine in humans. Influence of the
  induction agent. Bull. Schweiz. Akad. Med.

  Wiss., 23, 91.
- 100. Stowner, J., Theodorsen, I., and Bjelke, B. (1971).

  Sensitivity to gallemine and pencuronium with

  special reference to serum proteins. Brit. J.

  Assesth., 43, 953.
- 101. Showers, A.M., Constable, L.W., and Hunter, R.S.
  (1959). A clinical and phermacological comparison
  of chlorproposide and other sulphosyluress. Assals
  of the New York Academy of Sciences, 74, 609.
- 102. Thesleff, S. (1951). Pharmacologic and clinical experiments with 0.0. Succingleholine lodide.

  North Med., 46, 1045.
- 103. Sense, A. (1986). Prophylese des soccinylcholin bedingtes muskelleters mit dissepen. Annesthesist. 15. 263.

- 104. Torda, T.A., Burkhart, J., and Toh, W. (1972).

  The interaction of propanidid with summethonium and decamethonium. Ameesthesis, 27, 159.
- 105. Toscani, T., and Pasquali, P. (1967). Possibilita di interrezzione tra diazepan e d-tubocurarina. Minerva Anaesth., 33, 383.
- 106. Towler, M.L. (1962). The clinical use of diazepem in amulety states and depression. Journal of Neurology and Psychiatry, 3 (Suppl. 1), 568.
- 107. Verms, Y.S., and Sharms, P.L. (1971). Clinical experience with pencuronium bromide (NA 97):

  A new steroid neuromescular blocking agent.

  Indian J. Med. Res., 59, 69.
- 108. Vendramin, T., and Luzzato, A. (1968). Metodo hicmetrico di valutazione del dissepam endovenoso in neuroleptanniqueia. Chir. Ital., 20, 114.
- 109. Vergeno, F., Saccagna, C.A., Succero, G., and Buzile, C. (1960). Muscle releasant properties of diameter. Mineres Assesth., 35, 91.
- 110. Vergano, F., Raccagna, C.A., Raccaro, G., and Bezlie, C. (1970). Muscle relexant properties of dissepan. Surv. Anaesth., 14, 216.

- 111. Vickers, M.D., Wood-Smith, P.G., and Steward, H.C. (1978). Drugs in Anaesthetic Practice, 5th edn. P. 292, London : Butterworths.
- 112. Walker, C.R., Bandman, E., and Strohman, R.C. (1979). Discopen induces relaxation of chick embryo muscle fibre in vitro and inhibits myosin synthesis. Exp. Cell Res., 123, 285.
- 113. Walts, L.F., and Dillon, J.B. (1968). Duration of action of d-tubocurarine and gallamine.

  Amesthesiology, 29, 499.
- 114. Webb, S.N., and Bradshew, E.G. (1971) Diameter and neurosuscular blocking drugs. Brit. Med. J., 3. 640.
- 115. Webb, S.R., and Bradshaw, R.C. (1973). An importingtion into activity of dissepan at neuromagonlar junction. Brit. J. Anaesth., 45. 313.
- 116. Ebinden, G., and Rendell, L.O. (1967). Pharmacology of beneedlasspines: laboratory and clinical correlations. Advanc. Pharmacol., 5, 213.